Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 498
Healthy volunteers: no

Brief summary:
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes. Participants will be treated with insulin degludec and insulin glargine during two different periods. Which treatment participants get first is decided by chance. Both medicines are approved for use in humans and available on the market. They can already be prescribed by participants' doctors. Participants will get pre-filled insulin pens to inject these insulins with. The study will last for about 41 weeks. Participants will visit the clinic 13 times and have 27 phone calls with the study doctor or study staff. At 12 of the clinic visits they will take blood samples. In order to evaluate the changes in participants' blood sugar level over time, participants will be asked to wear a small (35 millimetres (mm) x 5 mm) sensor on the back of participants' upper arm 3 times during the study. Each time participants must wear the sensor for 2 weeks. This sensor is called FreeStyle Libre Pro®. It has a very small tip which is 0.4 mm thick and is inserted 5 mm under participants' skin. Please note that participants will not be able to see the sensor readings while wearing it. The study doctor will show participants the readings when participants return to the clinic. Participants will be asked to fill in a diary in between visits. Participants will have contact with the study doctor or study staff each week. This is to adjust the dose of participants' study medicines and to ensure that participants are well. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Detailed description:

Arms:
arm 1: Participants will receive insulin degludec in period 1 and 2 in a cross-over manner. arm 2: Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.

Interventions: intervention 1: Insulin degludec intervention 2: Insulin glargine
Intervention descriptions: intervention 1: Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial. intervention 2: Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.

Protocol document:
Prot_000.pdf: 
Cover Page for Protocol 
 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT03687827 
Sponsor trial ID: 
NN1250-4419 
Official title of study: 
A randomised, cross-over, open-label, multi-centre trial 
comparing the effect of insulin degludec and insulin glargine 
100U/mL, with or without OADs in subjects with type 2 
diabetes using flash glucose monitoring 
Document date 
04 May 2020 
 


/LQN
/LQN
/LVWRIFRQWHQWV
3URWRFRO 
$WWDFKPHQW,DQG,,
&21),'(17,$/
'DWH
1RYR1RUGLVN
9HUVLRQ
6WDWXV
,QVXOLQGHJOXGHF7UHVLED
7ULDO,'11
&OLQLFDO7ULDO5HSRUW
$SSHQGL[
0D\

)LQDO
3URWRFRODQGSURWRFRODPHQGPHQWV
CONFIDENTIAL
 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
1 of 68
Protocol
Protocol title: A randomised, cross-over, open-label, multi-centre  trial comparing the effect  of 
insulin degludec and insulin glargine 100U/mL, with or without OADs in subjects with type 2 
diabetes using flash glucose monitoring
SWITCH PRO
Substance: insulin degludec/insulin glargine 100U/mL
Universal Trial Number: U1111-1203-0580
EUdraCT Number: 2017-004047-20
Trial phase: 4
In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”.
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
2 of 68
Table of Contents   
Page
Table of Contents........................................................................................................................................2
1
Synopsis................................................................................................................................................5
2
Flowchart .............................................................................................................................................8
3
Introduction .......................................................................................................................................12
3.1
Trial rationale..........................................................................................................................12
3.2
Background.............................................................................................................................12
3.2.1
Therapeutic area – type 2 diabetes mellitus.............................................................12
3.2.2
Insulin degludec.....................................................................................................12
3.2.3
Insulin glargine 100U/mL ......................................................................................13
3.2.4
Flash Glucose Monitoring......................................................................................13
3.3
Benefit-risk assessment ...........................................................................................................13
4
Objectives and endpoints...................................................................................................................14
4.1
Primary, secondary and exploratory objective(s)......................................................................14
4.2
Primary, secondary and exploratory endpoints.........................................................................15
4.2.1
Primary endpoint ...................................................................................................15
4.2.2
Secondary endpoints ..............................................................................................15
4.2.2.1
Confirmatory secondary endpoints ...................................................15
4.2.2.2
Supportive secondary endpoints .......................................................15
4.2.3
Exploratory endpoints............................................................................................15
5
Trial design ........................................................................................................................................16
5.1
Overall design.........................................................................................................................16
5.2
Subject and trial completion....................................................................................................17
5.3
End of trial definition..............................................................................................................18
5.4
Scientific rationale for trial design...........................................................................................18
5.5
Justification for dose ...............................................................................................................18
6
Trial population .................................................................................................................................19
6.1
Inclusion criteria .....................................................................................................................19
6.2
Exclusion criteria ....................................................................................................................20
6.3
Lifestyle restrictions................................................................................................................21
6.4
Screen failures ........................................................................................................................21
6.5
Run in exclusion criteria..........................................................................................................21
6.6
Run in failures.........................................................................................................................21
6.7
Randomisation criteria ............................................................................................................22
7
Treatments .........................................................................................................................................22
7.1
Treatments administered .........................................................................................................22
7.1.1
Investigational medicinal products .........................................................................22
7.1.2
Non-investigational medicinal products..................................................................22
7.2
Medical devices ......................................................................................................................23
7.3
Dose modification...................................................................................................................23
7.4
Method of treatment assignment..............................................................................................24
7.5
Blinding..................................................................................................................................24
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
3 of 68
7.6
Preparation/Handling/Storage/Accountability..........................................................................24
7.7
Treatment compliance.............................................................................................................25
7.8
Concomitant medication..........................................................................................................25
7.9
Treatment after the end of the trial...........................................................................................25
8
Discontinuation/Withdrawal criteria ................................................................................................26
8.1
Discontinuation from trial .......................................................................................................26
8.2
Withdrawal from the trial ........................................................................................................26
8.2.1
Replacement of subjects.........................................................................................27
8.3
Lost to follow-up.....................................................................................................................27
9
Trial assessments and procedures .....................................................................................................27
9.1
Efficacy assessments...............................................................................................................28
9.1.1
FGM......................................................................................................................28
9.1.1.1
FGM Reader setting .........................................................................28
9.1.1.2
Fitting and removal of the FGM sensor.............................................29
9.1.1.3
Duration of FGM periods .................................................................29
9.1.1.4
Wearing of the FGM sensor..............................................................29
9.1.1.5
Transfer of FGM data.......................................................................30
9.1.2
Self-measured plasma glucose................................................................................30
9.1.3
Clinical efficacy laboratory assessments.................................................................31
9.2
Adverse events........................................................................................................................31
9.2.1
Time period and frequency for collecting AE and SAE information........................31
9.2.2
Method of detecting AEs and SAEs .......................................................................32
9.2.3
Follow-up on AEs and SAEs..................................................................................32
9.2.4
Regulatory reporting requirements for SAEs ..........................................................32
9.2.5
Cardiovascular and death events.............................................................................33
9.2.6
Disease-related events and/or disease-related outcomes not qualifying as an AE 
or SAE...................................................................................................................33
9.2.7
Pregnancies and associated adverse events .............................................................33
9.2.8
Medical device incidents (including malfunctions).................................................34
9.2.9
Technical complaints .............................................................................................34
9.3
Treatment of overdose.............................................................................................................34
9.4
Safety assessments ..................................................................................................................34
9.4.1
Physical examinations............................................................................................35
9.4.2
Vital signs..............................................................................................................35
9.4.3
Clinical safety laboratory assessments....................................................................35
9.4.4
Eye Examination....................................................................................................36
9.4.5
Pharmacokinetics...................................................................................................36
9.4.6
Pharmacodynamics ................................................................................................36
9.4.7
Genetics.................................................................................................................36
9.4.8
Biomarkers ............................................................................................................36
9.5
Insulin dose.............................................................................................................................36
9.6
Health economics – PRO questionnaires..................................................................................37
10
Statistical considerations ...................................................................................................................37
10.1
Sample size determination.......................................................................................................37
10.2
Definition of analysis sets........................................................................................................38
10.3
Statistical analyses ..................................................................................................................38
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
4 of 68
10.3.1
Primary endpoint ...................................................................................................38
10.3.2
Secondary endpoints ..............................................................................................40
10.3.3
Exploratory endpoints............................................................................................41
10.4
Pharmacokinetic and/or pharmacodynamic modelling .............................................................42
11
References ..........................................................................................................................................43
12
Appendices .........................................................................................................................................46
Abbreviations and Trademarks.......................................................................................46
Appendix 1
Clinical laboratory tests. ..................................................................................................48
Appendix 2
Trial governance considerations......................................................................................49
Appendix 3
Adverse events: definitions and procedures for recording, evaluation, follow-up, 
Appendix 4
and reporting .....................................................................................................................................58
Contraceptive guidance and collection of pregnancy information .................................62
Appendix 5
Technical complaints: Definition and procedures for recording, evaluation, follow-
Appendix 6
up and reporting ................................................................................................................................65
Country-specific requirements ........................................................................................66
Appendix 7
Titration guideline............................................................................................................67
Appendix 8
Attachment I Global list of key staff and relevant departments and suppliers
Attachment II Country list of key staff and relevant departments, if applicable for the individual 
country
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
5 of 68
1
Synopsis
Rationale:
The overall purpose of this trial is to investigate how insulin degludec (IDeg) influences glycaemic 
control compared to insulin glargine 100U/mL (IGlar 100U/mL), using flash glucose monitoring 
(FGM) in subjects with type 2 diabetes mellitus (T2DM). The accuracy and the widespread  
integration of FGM in clinical practice of today, provides a rationale for evaluating if the previously 
shown hypoglycaemia benefits with IDeg, translate into more time in glycaemic range and lower 
glycaemic variability versus the comparator. 
Objectives and endpoints:
Primary objective:
The primary objective is to compare the effect on glycaemic control of IDeg versus IGlar 100U/mL
in a population of T2DM subjects with or without oral anti-diabetic drugs (OADs), using FGM.
Estimand:
The primary estimand is the treatment difference between IDeg and glargine with respect to percent 
time spent in glycaemic target range for all randomised subjects that can use the FGM sensor and 
adhere to at least 18 weeks of treatment on both insulins. An intercurrent event for the primary 
estimand is lack of effect from any of the insulins leading to a need for initiation of other diabetes 
medication(s). As described in section 8.1 in the protocol, treatment intensification may result in 
trial discontinuation. . The primary estimand will handle these intercurrent events as withdrawals 
and only use data from completers. The primary estimand is the principle stratum direct effect for 
the population of completers.
The population level summary statistics is the average percent of time spent in glycaemic target 
during maintenance for completers. For comparing the two treatments the relevant summary is the 
difference in the means.
Primary endpoint:
Percentage of time spent in glycaemic target range 70-180 mg/dL (3.9–10.0 mmol/L) both 
inclusive, during the 2-week maintenance period using FGM (Visit 19-21 (week 16-17) and Visit
37-39 (week 34-35)).
Overall design:
This is a randomised, cross-over, open-label, multi-centre, multinational, active controlled trial in 
adult subjects with type 2 diabetes treated with basal insulin with or without OADs with a 2 weeks 
run-in period to ensure compliance and tolerability of the FGM requirements.
At randomisation (Visit 3), subjects will discontinue pre-trial basal insulin and be randomised in a 
1:1 manner to the 2 treatment sequences:
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
6 of 68
!
IDeg once daily ± OADs followed by IGlar 100U/mL once daily ± OADs 
!
IGlar 100U/mL once daily ± OADs followed by IDeg once daily ± OADs 
Key inclusion criteria:
!
Male or female, age ≥ 18 years at the time of signing informed consent
!
Diagnosed with type 2 diabetes mellitus ≥ 180 days prior to the day of screening
!
Subjects fulfilling at least one of the below criteria:
o
Experienced at least one severe hypoglycaemic episode within the last year prior to 
screening (according to the American Diabetes Association definition, January 
2018)*
o
Moderate renal impairment defined as estimated glomerular filtration rate (eGFR) 
value of 30-59 mL/min/1.73 m2 as defined by KDIGO 20121 at screening
o
Known hypoglycaemic unawareness as indicated by the investigator according to 
Clarke’s questionnaire question 82 at screening
o
Treated with insulin for more than 5 years
o
Episode of hypoglycaemia (defined a glucose alert value of  70 mg/dL (3.9 mmol/L) 
or less, i.e. Level 1)3 within the last 12 weeks prior to screening visit
!
Treated with any basal insulin  ≥ 90 days prior to the day of screening with or without any 
of the following anti-diabetic drugs :
o
Metformin
o
Dipeptidyl peptidase-4 inhibitor
o
Sodium-glucose co-transporter 2 inhibitor
o
Alpha-glucosidase-inhibitors (acarbose)
o
Thiazolidinediones
o
Marketed oral combination products only including the products listed above
!
HbA1c ≤9.5% (80 mmol/mol) at screening confirmed by central laboratory analysis
!
BMI ≤ 45 kg/m2
*Hypoglycaemia associated with severe cognitive impairment requiring external assistance for 
recovery
Key exclusion criteria:
!
Treatment with any medication for the indication of diabetes or obesity other than stated in 
the inclusion criteria within the past 90 days prior to the day of screening. However, 
intermittent bolus insulin treatment for periods of no longer than 14 days are permitted prior 
to the day of screening.
!
Anticipated initiation or change in concomitant medications  known to affect weight or 
glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).
!
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a 
pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
7 of 68
another suitably qualified health care provider within the past 90 days prior to screening or 
in the period between screening and run-in
Randomisation criteria:
!
Subject able and willing to adhere to the protocol including requirements and tolerability in 
regards to wearing the FreeStyle Libre Pro sensor, based on the investigator’s opinion.
Number of subjects:
Number of subjects planned to be screened: 674
Number of subjects planned to enter-run-in period: 502
Number of subjects planned to be randomised: 472
Treatment groups and duration:
The total duration of the trial will be approximately 41 weeks: 2 weeks screening period, a 2 weeks 
run-in period, a 36 weeks treatment period and a 1 week follow-up.
This is a cross-over trial and each randomised subject will receive both Investigational Medicinal 
Products (IMP) for 18 weeks, and both treatment periods will start with a 16 weeks titration period 
followed by a 2 weeks maintenance period. At cross-over subjects will be switched to the other IMP 
according to local label.
Subjects using OADs prior to the trial according to inclusion criteria, should continue that treatment 
throughout the trial with no changes of dose unless for safety reason.
  
Trial products:
Investigational Medicinal Products:
!
Test products: Insulin degludec (Tresiba®) 100 U/ml, 3 ml PDS290 pen injector 
(FlexTouch®)
!
Reference therapy: Insulin glargine (Lantus®) 100 U/ml, 3 mL pre-filled pen injector 
(SoloStar®)
CONFIDENTIAL


Protocol
     
Date:
01 June 2018
Status:
Final
1RYR1RUGLVN
Trial ID: NN1250-4419
     
Version:
3.0
Page:
8 of 68
2
Flowchart
Treatment period 1
Treatment period 2
End of treatment
Follow-up
Screening
Run-in
Randomisation
Titration period 1
Maintenance 
period 1
Titration period 2
Maintenance 
period 2
Visit
V1
V2
V3
P4-P6
V7
P8-
P10
V11
P12-
P14
V15
P16-
P18
V19
P20
V21
P22-
P24
V25
P26-
P28
V29
P30-
P32
V33
P34-P36
V37
P38
V39
P40
Timing of Visit (Weeks)
-4
-2
0
1-3
4
5-7
8
9-11
12
13-15
16
17
18
19-21
22
23-25
26
27-29
30
31-33
34
35
36
37
Visit Window (Days)
+10
-3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+5
SUBJECT RELATED INFORMATION AND 
ASSESSMENTS
Informed consent
X
Demography1
X
In/exclusion criteria
X
X
Run-in exclusion criteria
X
X
Childbearing potential
X
Hypoglycaemia Unawareness2
X
Concomitant illness/medical history
X
Concomitant medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medication (diabetes)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Diabetes complications
X
Diagnosis of diabetes
X
Body measurements
X
X
X
X
                                               
1 Demography consists of date of birth or year of birth, sex, ethnicity and race (according to local regulation see Appendix 7).
2 Information on hypoglycaemia unawareness will be recorded according to Clarke's questionnaire, question 82. The investigator must ask the subject in the following way: "To what extent can you tell by your 
symptoms that your blood glucose is low?" Subjects answering 'never, rarely or sometimes' are considered to have impaired awareness of hypoglycaemia


Protocol
     
Date:
01 June 2018
Status:
Final
1RYR1RUGLVN
Trial ID: NN1250-4419
     
Version:
3.0
Page:
9 of 68
Treatment period 1
Treatment period 2
End of treatment
Follow-up
Screening
Run-in
Randomisation
Titration period 1
Maintenance 
period 1
Titration period 2
Maintenance 
period 2
Visit
V1
V2
V3
P4-P6
V7
P8-
P10
V11
P12-
P14
V15
P16-
P18
V19
P20
V21
P22-
P24
V25
P26-
P28
V29
P30-
P32
V33
P34-P36
V37
P38
V39
P40
Timing of Visit (Weeks)
-4
-2
0
1-3
4
5-7
8
9-11
12
13-15
16
17
18
19-21
22
23-25
26
27-29
30
31-33
34
35
36
37
Visit Window (Days)
+10
-3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+5
Randomisation criteria
X
Discontinuation/Withdrawal criteria
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
EFFICACY
Pre-breakfast SMPG (3 days prior to next 
contact)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
HbA1c
X
X
X
X
X
X
X
X
X
X
X
X
SAFETY
Adverse event
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Medication Error
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Technical Complaints
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Biochemistry
X
X
X
Pregnancy test
X
Vital signs
X
X
X
X
Physical examination
X
X
X
X
Eye examination
X
OTHER ASSESSMENTS
FGM Sensor Data
FGM fitting
X
X
X


Protocol
     
Date:
01 June 2018
Status:
Final
1RYR1RUGLVN
Trial ID: NN1250-4419
     
Version:
3.0
Page:
10 of 68
Treatment period 1
Treatment period 2
End of treatment
Follow-up
Screening
Run-in
Randomisation
Titration period 1
Maintenance 
period 1
Titration period 2
Maintenance 
period 2
Visit
V1
V2
V3
P4-P6
V7
P8-
P10
V11
P12-
P14
V15
P16-
P18
V19
P20
V21
P22-
P24
V25
P26-
P28
V29
P30-
P32
V33
P34-P36
V37
P38
V39
P40
Timing of Visit (Weeks)
-4
-2
0
1-3
4
5-7
8
9-11
12
13-15
16
17
18
19-21
22
23-25
26
27-29
30
31-33
34
35
36
37
Visit Window (Days)
+10
-3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+5
FGM removal3
X
X
X
PRO questionnaires
Diabetes Pen Experience Measure
X
X
X
X
TRIM-diabetes device
X
X
X
Confirmation of unchanged OADs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
TRIAL MATERIAL
Dose of trial insulin
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Dispensing visit
X
X
X
X
X
X
X
X
X
X
Drug accountability
X
X
X
X
X
X
X
X
X
X
X
REMINDERS
X
X
X
X
X
X
X
X
X
X
X
X
X
IWRS session
X
X
X
X
X
X
X
X
X
X
X
X
Hand out ID card
X
Hand out and instruct in Pro device
X
X
X
Hand out directions for use
X
X
Training in trial product, pen-handling
X
X
Hand out and instruct in BG-meter
X
Hand out and instruct in diary
X
X
X
X
X
X
X
X
X
X
                                               
3 Confirmation that 14 days data have been collected should be obtained, as described in section 9.1.1.4


Protocol
     
Date:
01 June 2018
Status:
Final
1RYR1RUGLVN
Trial ID: NN1250-4419
     
Version:
3.0
Page:
11 of 68
Treatment period 1
Treatment period 2
End of treatment
Follow-up
Screening
Run-in
Randomisation
Titration period 1
Maintenance 
period 1
Titration period 2
Maintenance 
period 2
Visit
V1
V2
V3
P4-P6
V7
P8-
P10
V11
P12-
P14
V15
P16-
P18
V19
P20
V21
P22-
P24
V25
P26-
P28
V29
P30-
P32
V33
P34-P36
V37
P38
V39
P40
Timing of Visit (Weeks)
-4
-2
0
1-3
4
5-7
8
9-11
12
13-15
16
17
18
19-21
22
23-25
26
27-29
30
31-33
34
35
36
37
Visit Window (Days)
+10
-3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+5
Collect diary
X
X
X
X
X
X
X
X
X
X
First date on trial product
X
X
First dose on trial product
X
X
Cross-over
X
Last date on trial product
X
X
Last dose on trial product
X
X
End of treatment
X
End of trial
X
Sign-off case-book
X


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
12 of 68
3
Introduction
3.1
Trial rationale
The overall purpose of this trial is to investigate how insulin degludec (IDeg) influences glycaemic 
control compared to insulin glargine 100U/mL (IGlar 100U/mL), using FGM.
Since significant technical improvements have been made in the precision, accuracy, and usability 
of modern, continuous or flash, glucose monitoring devices, their relevance in ambulatory diabetes 
care is increasing. These devices, measuring glucose concentration in interstitial fluid, are widely 
used in clinical practice, considered an established part of diabetes management and will be 
increasingly used going forward 4 5 . Data on IDeg, generated by modern glucose monitoring 
technique, are therefore repeatedly asked for by key opinion leaders and health care professionals. 
Furthermore, as the efficacy and safety of IDeg has been evaluated in an extensive clinical 
development programme6; the purpose of this trial is not to focus on hypoglycaemia risk, evaluated 
by hypoglycaemia forms, but rather to evaluate if the previously shown hypoglycaemia benefits 
with IDeg translate into more time in glycaemic target range 70-180 mg/dL (3.9-10.0 mmol/L) less 
hypoglycaemia and lower glycaemic variability versus the comparator. 
Finally as the safety profiles of both investigational medicinal products are well characterised, a 
selective safety data collection approach will be used7.
3.2
Background
3.2.1
Therapeutic area – type 2 diabetes mellitus
T2DM is characterised by insulin resistance, impaired insulin secretion, increased hepatic glucose 
output due to glucagon dysregulation and thus chronic hyperglycaemia8. A number of landmark 
studies have demonstrated the importance of maintaining tight glycaemic control to reduce the risk 
of long-term complications associated with diabetes9.
The current treatment cascade follows a stepwise approach comprising of lifestyle changes in 
combination with pharmacological intervention. Metformin is recommended as initial 
pharmacological therapy, followed by combination therapy with other OADs, GLP-1 receptor 
agonists or insulin as the disease progresses10. 
3.2.2
Insulin degludec
IDeg is an insulin analogue with unique pharmacological properties and a long duration of action, 
beyond 42 hours11. IDeg provides similar glycaemic control to comparators with a 14–18% lower 
risk of confirmed hypoglycaemia and a 23–38% lower risk of nocturnal confirmed hypoglycaemia 
compared to IGlar 100U/mL in T2DM (phase 3a trials)12, 13. Moreover, in the SWITCH 2 trial 
(T2DM, phase 3b trial) IDeg was associated with a 23% lower risk of overall confirmed 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
13 of 68
symptomatic hypoglycaemia, a 25% lower risk of nocturnal confirmed symptomatic hypoglycaemia 
and a 51% lower risk of severe hypoglycaemia compared to IGlar 100U/mL11. The hypoglycaemic 
risk reduction for IDeg compared to glargine 100 U/mL was more pronounced in the maintenance 
period in all trials11 12 13
.
IDeg is developed in two strengths (100 U/mL and 200 U/mL) that are demonstrated to be bio-
equivalent in clinical pharmacology trials. IDeg has been approved in more than 90 countries 
globally and is indicated for treatment of diabetes mellitus as monotherapy, in combination with 
oral anti-diabetic agents and GLP-1 receptor agonist, and as part of a basal-bolus insulin regimen in 
adults and children from the age of 1 year (GLP-1 receptor agonist co-usage and paediatric 
indication <18 years is not an approved indication in all countries with market authorisation). For 
further details please refer to the current version of the IDeg IB6 and any updates thereof, and local 
labelling.
3.2.3
Insulin glargine 100U/mL
IGlar 100U/mL is a long-acting insulin analogue, indicated for treatment of diabetes mellitus in 
combination with oral antidiabetic agents and as part of a basal-bolus insulin regimen14 15.
3.2.4
Flash Glucose Monitoring
The FreeStyle Libre Pro FGM system will be used in this trial and referred as FGM system.
It is a CGM system, FDA approved and European Union European Conformity (CE) labelled. It is 
indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes (see 
Operator’s manual).
The FGM sensor, applied on the subject’s upper back arm, uses wired enzyme technology for 
tracking glucose concentration in the body’s interstitial fluid. The sensor is factory calibrated and 
will not require calibration by the subjects16.
The FGM reader will show continuous glucose measurements retrospectively at time of scanning of 
the sensor, allowing identification of intra and interday glycaemic excursions17.
3.3
Benefit-risk assessment
The main expected benefit for the subjects participating in this trial is the potential improved 
glycaemic control under an optimised basal treatment. This aim will be achieved with a 
recommended titration ‘basal insulin dose adjusted algorithm’ at different plasma glucose levels.
The individual subjects will receive medical care with close contact to the clinical sites (i.e. weekly 
contacts) and the anticipated treatment regimen is expected to be equal to or better than the previous 
treatment regimen experienced before trial initiation. However, subjects will have to spend some 
extra time monitoring and recording data (e.g. SMPG values) every day as well as in connection to 
visits to the clinic and phone contacts.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
14 of 68
The high frequency of contacts between the subject/investigator and the thorough evaluation of 
SMPG values will provide the opportunity for optimising the titration of basal insulin based on 
SMPG values and thereby contributing to obtain improved glycaemic control.
The anticipated side effects are associated with the known and established safety profile of the 
registered trial products (e.g.: hypoglycaemia, hypersensitivity reactions for the basal insulins) and 
FGM sensor (mild local skin irritation for the FGM sensor's adhesive patch). The side effects will 
be mitigated by the close supervision of the trial subjects. 
The maximum trial duration for each subject is approximately 41 weeks and the treatment duration 
for a subject is planned to be 36 weeks. 
Trial products will be provided by Novo Nordisk free of charge during the subjects’ participation in 
the trial. Subjects will receive IDeg and IGlar 100U/mL in prefilled pens. Subjects will also receive 
a glucose meter including auxiliaries as well as diaries for reporting of SMPGs and insulin doses.
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of IDeg and IGlar 100U/mL may be found respectively in the current 
version of:
!
insulin degludec IB18
!
insulin glargine 100U/ml SmPC14, US Prescribing Information15, or local labelling
!
FreeStyle Libre Pro Operator's manual
Based on the above, it can be concluded that the clinical benefits outweigh the potential risks for 
subjects participating in this trial.
4
Objectives and endpoints
4.1
Primary, secondary and exploratory objective(s)
The primary objective is to compare the effect on glycaemic control of IDeg versus IGlar 100U/mL
in a population of T2DM subjects with or without OADs, using FGM.
Estimand:
The primary estimand is the treatment difference between IDeg and IGlar 100U/mL with respect to 
percent time spent in glycaemic target range for all randomised subjects that can use the FGM 
sensor and adhere to at least 18 weeks of treatment on both insulins. An intercurrent event for the 
primary estimand include lack of effect from any of the insulins leading to a need for initiation of 
other diabetes medication(s). As described in section 8.1 in the protocol, treatment intensification 
may result in trial discontinuation. . The primary estimand will handle these intercurrent events as 
withdrawals and only use data from completers.  The primary estimand is the principle stratum 
direct effect for the population of completers.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
15 of 68
The population level summary statistics is the average percent of time spent in glycaemic target 
during maintenance for completers. For comparing the two treatments the relevant summary is the 
difference in the means.
4.2
Primary, secondary and exploratory endpoints 
4.2.1
Primary endpoint
Percentage of time spent in glycaemic target range 70-180 mg/dL (3.9–10.0 mmol/L) both 
inclusive, during the 2-week maintenance period using FGM (Visit 19-21 (week 16-17) and Visit 
37-39 (week 34-35)).
4.2.2
Secondary endpoints
4.2.2.1
Confirmatory secondary endpoints
N/A
4.2.2.2
Supportive secondary endpoints
!
Percentage of time spent in tight glycaemic target range 70-140 mg/dL (3.9–7.8 mmol/L) 
both inclusive, during the 2-week maintenance periods using FGM (Visit 19-21 (week 16-
17) and Visit 37-39 (week 34-35)).
!
Percentage of time spent in nocturnal glycaemic target range 70-140 mg/dL (3.9-7.8 
mmol/L) both inclusive, in the nocturnal period (00:01 am – 05:59 am both inclusive) 
during the 2-week maintenance periods using FGM (Visit 19-21 (week 16-17) and Visit 37-
39 (week 34-35)).
!
HbA1c(% and mmol/mol) after two weeks of maintenance periods (Visit 19-21 (week 16-
17) and Visit 37-39 (week 34-35)).
!
Mean glucose levels (mg/dL and mmol/L) during the 2-week maintenance periods using 
FGM (Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35)).
4.2.3
Exploratory endpoints
!
Glycaemic variability calculated as standard deviation (mg/dL and mmol/L) and coefficient 
of variation (% ) of glucose levels during the 2-week maintenance treatment using FGM
(Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35)).
!
Mean insulin dose (IU) during the 2-week maintenance treatment period (Visit 19-21 (week 
16-17) and Visit 37-39 (week 34-35)).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
16 of 68
!
Percentage of time spent in the hypoglycaemia alert range (Level 1) 54-69 mg/dL (3.0-3.8 
mmol/L) both inclusive, during the 2-week maintenance periods using FGM (Visit 19-21 
(week 16-17) and Visit 37-39 (week 34-35)).
!
Percentage of time spent in the clinically significant hypoglycaemic range (Level 2) 
<54mg/dL (<3.0 mmol/L) during the 2-week maintenance periods using FGM (Visit 19-21 
(week 16-17) and Visit 37-39 (week 34-35)).
!
Number of clinically significant hypoglycaemic episodes (Level 2) <54mg/dL (<3.0 
mmol/L) for at least 15 minutes during the 2-week maintenance periods using FGM (Visit 
19-21 (week 16-17) and Visit 37-39 (week 34-35)).
!
Number of clinically significant hypoglycaemic episodes (Level 2) <54mg/dL (<3.0 
mmol/L) for at least 15 minutes in the nocturnal period (00:01-05:59 AM, both inclusive) 
during the 2-week maintenance periods using FGM (Visit 19-21 (week 16-17) and Visit 37-
39 (week 34-35)).
5
Trial design
5.1
Overall design
This trial is a 41-week, randomised, cross-over, open-label, multi-center, active controlled trial 
comparing the effect of insulin IDeg versus insulin IGlar 100U/mL, with or without OADs in 
subjects with type 2 diabetes using flash glucose monitoring.
The trial includes a screening visit (Visit 1), followed by a 2-week run-in period for eligibility 
assessment in regards to adherence to FGM requirements. At randomisation (Visit 3), eligible 
subjects will be randomised 1:1 into one of two treatment periods receiving either IDeg or IGlar 
100U/mL. Each treatment period consist of a 16-week titration period followed by a 2-weeks 
maintenance period where subjects will wear the FreeStyle Libre Pro Sensor.
After the first titration and maintenance period the subject will switch to the other trial product, with 
dose adjustment according to local label, performing the same assessments as in the first treatment 
period (16-week titration period followed by a 2-weeks maintenance period).
For details of the dosing of IDeg and IGlar 100U/mL, refer to Appendix 8.
The follow-up period is 1 week. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
17 of 68
IDeg U100 OD ± OADs
IGlar U100 OD ± OADs
IDeg U100 OD ± OADs
IGlar U100 OD ± OADs
V2
V1
V21
V37
V39
V19
FGM
FGM
FGM
FGM
Maintenan ce 
period 1
Maintenan ce 
period 2
-4
-2
V3
0
Run-in
period
FGM
16
18
34
36
Titration period 1
Titration period 2
Screening 
period
Cross over
Treatment period 2
18 weeks
Treatment period 1
18 weeks
37 weeks
V40
End of 
treatment
End of trial
Follow-up 
period
Randomisation
Figure 1 Trial design
5.2
Subject and trial completion
Approximately 674 subjects will be screened to achieve 472 subjects randomly assigned to trial 
product.
Approximately 502 subjects are planned to be included in the run-in period.
Trial period completion for a subject:
Trial period completion is defined as when the randomised subject has completed the final 
scheduled visit ('end of trial' according to the flowchart).
'Date of trial completion' is the date the subject completed the final scheduled visit.
Treatment period completion for a subject: 
Treatment period completion is defined as when the randomised subject has received the required 
treatment, and attended the 'end of treatment' visit according to the flowchart.
The treatment period 1 starts at Visit 3 and is defined as when the randomised subject has received 
the required treatment for at least 18 weeks and attended Visit 21 according to the flowchart.
The treatment period 2 starts at Visit 21 and is defined as when the randomised subject has received 
the required treatment for at least 18 weeks and attended Visit 39 according to the flowchart.
Required treatment:
Completion of both treatment periods is required for contribution to the analysis. Only the data from 
subjects completing 16 weeks of titration and 2 weeks of maintenance wearing the FreeStyle Libre 
Pro device, with both trial products, will be used in the outcome analyses.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
18 of 68
5.3
End of trial definition
The end of the trial is defined as the date of the last visit of the last subject in the trial. 
5.4
Scientific rationale for trial design
The cross-over design is chosen to reduce the number of subjects needed to obtain sufficient power. 
An open labelled trial design is chosen to minimize inconvenience for the subjects as IDeg and 
IGlar 100U/mL are presented in different pen injector systems. Full blinding would require a double 
dummy approach or the use of syringes and needles.
The trial population are adult male and female subjects with T2DM with an HbA1c equal or below 
9.5% while treated with any basal insulin with or without OADs for at least 90 days, and who 
recently have experienced hypoglycaemia or have increased risk of severe hypoglycaemia. This 
population is chosen in order to reflect a general T2DM population, not excluding subjects with a 
high risk of hypoglycaemia. 
Subjects requiring treatment with basal and bolus are not included to avoid the confounding element 
of bolus insulin.
A 16 weeks titration period is selected as data from previous IDeg trials demonstrate that subjects 
previously treated with basal insulin ± OADs can achieve improved and stable HbA1c levels within 
16 weeks of titration11.
The treat-to-target approach will be applied in both treatment arms in order to optimise titration and 
glycaemic control throughout the trial according to Appendix 8. The treat to target trial requires 
good subject’s adherence, thus subjects with an HbA1c above 9.5% have been excluded as poor 
compliance is a likely cause of elevated HbA1c amongst the T2DM population.
A body mass index (BMI) limit of ≤ 45.0 kg/m2 includes as broad a population as possible while 
excluding very obese individuals who might be extremely insulin resistant.
Subjects with unstable proliferative retinopathy requiring acute treatment, hepatic or severe renal 
impairment or uncontrolled severe hypertension and subjects who with the 26 weeks prior to 
screening have experienced a cardiovascular event as defined in the exclusion criteria are not 
eligible for inclusion in this trial due to the treat-to-target approach and their need for more 
individualised therapy.
5.5
Justification for dose
At randomisation (Visit 3) pre-trial insulin treatments will be discontinued and eligible subjects are 
randomised 1:1 into one of two treatment sequences:
!
IDeg OD ± OADs followed by IGlar 100U/mL OD ± OADs
!
IGlar 100U/mL OD ± OADs followed by IDeg OD ± OADs
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
19 of 68
At randomisation and at cross over, subjects will initiate treatment according to local labels, no 
maximum trial insulin dose is specified. 
The dosing time should preferably be kept throughout the entire treatment period.
Both IMPs should be injected subcutaneously into the thigh, upper arm (deltoid area) or the 
abdomen. The chosen region should be the same throughout the trial for each trial product. Rotation 
of injection sites within a given region is recommended
Subject treated with one or more allowed OAD(s), see inclusion criteria, Section 6.1, should 
continue their pre-trial OAD(s) treatment throughout the trial, with no change of dose unless for 
safety reasons.
6
Trial population
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
6.1
Inclusion criteria
Subjects are eligible to be included in the trial only if all of the following criteria apply:
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability 
for the trial
2. Male or female, age ≥ 18 years at the time of signing informed consent
3. Diagnosed with type 2 diabetes mellitus ≥ 180 days prior to the day of screening
4. Subjects fulfilling at least one of the below criteria:
a.
Experienced at least one severe hypoglycaemic episode within the last year prior to 
screening (according to the ADA definition, January 2018) *
b. Moderate renal impairment defined as estimated glomerular filtration rate (eGFR) 
value of 30-59 mL/min/1.73 m2 as defined by KDIGO 20121 at screening
c.
Known hypoglycaemic unawareness as indicated by the investigator according to 
Clarke’s questionnaire question 8 2 at screening
d. Treated with insulin for more than 5 years
e.
Episode of hypoglycaemia (defined by a glucose alert value of  70 mg/dL (3.9 
mmol/L) or less, i.e. Level 1)3 within the last 12 weeks prior to screening visit
5. Treated with any basal insulin  ≥ 90 days prior to the day of screening with or without any 
of the following anti-diabetic drugs :
a.
Metformin
b. Dipeptidyl peptidase-4 inhibitor
c.
Sodium-glucose co-transporter 2 inhibitor
d. Alpha-glucosidase-inhibitors (acarbose)
e.
Thiazolidinediones
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
20 of 68
f.
Marketed oral combination products only including the products listed in criteria 5a-
5e
6. HbA1c ≤9.5% (80 mmol/mol) at screening confirmed by central laboratory analysis
7. BMI ≤ 45 kg/m2 
*Hypoglycaemia associated with severe cognitive impairment requiring external assistance for 
recovery
6.2
Exclusion criteria 
Subjects are excluded from the trial if any of the following criteria apply:
1. Known or suspected hypersensitivity to trial product(s) or related products. 
2. Previous participation in this trial. Participation is defined as signed informed consent.
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using adequate contraceptive methods (adequate contraceptive measures as 
required by local regulation or practice).
4. Receipt of any investigational medicinal product within 4 weeks before screening.
5. Any disorder which in the investigator’s opinion might jeopardise subject’s safety or 
compliance with the protocol.
6. Treatment with any medication for the indication of diabetes or obesity other than stated in 
the inclusion criteria within the past 90 days prior to the day of screening. However, 
intermittent bolus insulin treatment for periods of no longer than 14 days are permitted prior 
to the day of screening.
7. Anticipated initiation or change in concomitant medications  known to affect weight or 
glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).
8. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a 
pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or 
another suitably qualified health care provider within the past 90 days prior to screening or 
in the period between screening and run-in
9. Presence or history of malignant neoplasms within the past 5 years prior to the day of 
screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
10. Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina 
pectoris or transient ischaemic attack within the past 180 days prior to the day of screening
11. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic 
≥180 mmHg or diastolic ≥100 mmHg) at screening.
12. Impaired liver function defined as Alanine Aminotransferase (ALT) ≥2.5 times or Bilirubin 
>1.5 times upper normal limit at screening.
13. Renal impairment defined as estimated glomerular filtration rate (eGFR) value of eGFR <30 
mL/min/1.73m2  as defined by KDIGO 20121 at screening
14. Anticipated change in lifestyle affecting glucose control.
15. Currently using real time CGM or FGM system
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
21 of 68
6.3
Lifestyle restrictions
Change in lifestyle affecting glucose control must be avoided throughout the trial.
While wearing the FGM sensor, subjects will be asked to comply with requirements described in 
Section 9.1.1.4. 
6.4
Screen failures
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
eligible for participation according to in/exclusion criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet 
requirements from regulatory authorities. Minimal information includes demography, screen failure 
details, eligibility criteria, and any SAE. 
A screen failure session must be made in the IWRS and the screening failure form must be 
completed in the eCRF.
Individuals who do not meet the criteria for participation in this trial may not be rescreened. Re-
sampling is not allowed if the subject has failed one of the inclusion criteria or fulfilled one of the 
exclusion criteria related to laboratory parameters. However, in case of technical issues (e.g. 
haemolysed or lost), re-sampling is allowed for the affected parameters. 
6.5
Run in exclusion criteria
The subject must be excluded from the trial during the run-in period, if the following applies after 
screening and before or at randomisation:
1. Included in the trial in violation of the inclusion and/or exclusion criteria
2. Pregnancy
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
5. Initiating use of real time CGM or FGM other than use specified by protocol
6.6
Run in failures
Run-in failures are defined as subjects who are not eligible to be randomised (i.e. has met one of the 
run-in exclusion criteria or has not met the randomisation criteria). 
A screen failure session must be made in the IWRS and the screening failure form must be 
completed in the eCRF together with the reason for not continuing in the trial. 
No follow-up visit should take place and no additional assessments are needed. SAEs from run-in 
failures must be recorded by the investigator in the eCRF. Follow-up of SAEs must be carried out 
according to Appendix 4
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
22 of 68
6.7
Randomisation criteria
To be randomised, the following randomisation criteria must be answered "yes":
1. Subject able and willing to adhere to the protocol including requirements and tolerability in 
regards to wearing the FreeStyle Libre Pro sensor, based on the investigator’s opinion.
7
Treatments
7.1
Treatments administered
7.1.1
Investigational medicinal products
!
Trial products must only be used, if it appears clear and colourless.
!
Only needles provided or approved by Novo Nordisk must be used for administration of trial 
product. 
!
The investigator must document that directions for use are given to the subject orally and in 
writing at the first dispensing visit.  
Table 1
Trial products provided by Novo Nordisk A/S
Trial product name:
Insulin degludec (Tresiba®) 100 
U/mL
(IMP, test product)
Insulin glargine (Lantus®) 
100 U/ml
(IMP, reference therapy)
Dosage form:
Solution for injection
Solution for injection
Route of administration: 
Subcutaneous
Subcutaneous
Recommended initial dose/Unit 
dose strength(s)/ Dosage level(s):
Initial dose according to local label.
Changes of dose according to 
Appendix 8. 
Initial dose according to local label.
Changes of dose according to 
Appendix 8
Dosing instructions:
Once daily
Once daily
Packaging
3 ml PDS290 pen injector 
(FlexTouch®)
3 mL pre-filled pen injector 
(SoloStar®)
7.1.2
Non-investigational medicinal products
The following Non-Investigational Medicinal Products (NIMPs) will not be supplied by Novo 
Nordisk. However, they will be reimbursed if required according to local regulations.
!
Metformin, tablets for oral use
!
DPP-4i, tablets for oral use
!
SGLT2i, tablets for oral use
!
Thiazolidinedione, tablets for oral use
!
Alpha-glucosidase-inhibitor, tablets for oral use 
!
Tablets for oral use of marketed combination products only including the products listed 
above.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
23 of 68
For Slovakia please see Appendix 7 for Country-specific requirements
7.2
Medical devices
Non-investigational medical device(s):
!
Novo Nordisk needles for pen injectors (not longer than 6mm)
!
Blood glucose (BG) meter and auxiliaries
!
FGM devices (FreeStyle Libre Pro sensor and reader) and auxiliaries
Complaints related to the needles should be reported to local Novo Nordisk affiliate with a 
reference to trial ID (see Appendix 6).
For complaints related to the BG meter or the FGM devices, the investigator must contact the 
device manufacturer’s technical support according to operator’s manual provided with the devices
(see Appendix 4).
Training in BG meter:
At randomisation (Visit 3) subjects will be provided with a BG meter including auxiliaries and 
instructions for use. The subjects will be instructed in how to use the devices as indicated in the 
flowchart. 
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display. 
Training in FGM devices:
Novo Nordisk will ensure that trial site staffs receive appropriate training in regards to the use of 
the FGM devices. Furthermore site staff should familiarise themselves with the FGM operator’s 
manual before using the FGM devices.
Before each FGM period, subjects must be instructed according to Section 9.1.1.4 as indicated in 
the flowchart (Section 2). 
7.3
Dose modification
The dosing time should preferably be kept throughout the entire treatment period.
Local labelling requirements will be used at randomisation and cross over to initiate treatment. 
No maximum trial insulin dose is specified.
Insulin doses are adjusted according to blood/plasma glucose values as described in Appendix 8. 
Surveillance of insulin titration will be performed by Novo Nordisk.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
24 of 68
Diaries will be handed out at all clinics visits as indicated in the flowchart (Section 2) to report 
SMPG measurements and insulin doses as described in Sections 9.1.2 and 9.5. The recommended 
insulin doses will be individually calculated in the eCRF based on the SMPG measurements and the 
doses taken in accordance with the titration guideline described in Appendix 8. 
7.4
Method of treatment assignment
All subjects will be centrally randomised using an IWRS and assigned to the next available 
treatment according to randomisation schedule. Trial product will be dispensed at the trial visits 
summarised in the flowchart. 
7.5
Blinding
This is an open-label trial and the specific treatment for a subject will be assigned using an IWRS. 
The site will access the IWRS before the start of trial product administration for each subject. 
7.6
Preparation/Handling/Storage/Accountability
Only subjects enrolled in the trial may receive trial product and only authorised site staff may 
supply or administer trial product. 
!
Each trial site will be supplied with sufficient trial products for the trial on an on-going basis 
controlled by the IWRS. Trial product will be distributed to the trial sites according to 
screening and randomisation.
!
The investigator must confirm that appropriate temperature conditions have been maintained 
during transit for all trial products received and any discrepancies are reported and resolved 
before use of the trial products.
!
All trial products must be stored in a secure, controlled, and monitored (manual or 
automated) area in accordance with the labelled storage conditions with access limited to the 
investigator and authorised site staff.
!
The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditions. Additional details regarding handling of temperature deviations 
can be found in the TMM. 
!
Trial product that has been stored improperly must not be dispensed to any subject before it 
has been evaluated and approved for further use by Novo Nordisk.
!
The investigator is responsible for drug accountability and record maintenance (i.e. receipt, 
accountability and final disposition records).
!
Drug accountability should be performed at pen level per DUN.
!
Destruction of trial products can be performed on an ongoing basis and will be done 
according to local procedures after accountability is finalised by the site and reconciled by 
the monitor. 
!
Destruction of trial products must be documented in the IWRS. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
25 of 68
!
All returned, expired or damaged trial products (for technical complaint samples see 
Appendix 6) must be stored separately from non-allocated trial products. No temperature 
monitoring is required.
!
Non-allocated trial products including expired or damaged products must be accounted as 
unused, at the latest at closure of the trial site. 
!
The FGM sensors distributed to the sites will have to be stored according to Table 2 and 
temperature monitoring is required.
Table 2 FreeStyle Libre Pro sensor storage conditions
Device name
Storage conditions
(not-in-use)
In-use conditions
In-use timeb
Freestyle Libre Pro sensor
Store (4°C – 25°C / 39°F - 77°F)
Do not freeze
-
Up to 14 days
b In-use time starts when sensor has been fitted
7.7
Treatment compliance
Throughout the trial, the investigator will remind the subjects to follow the trial procedures and 
requirements to ensure subject compliance. Furthermore, the investigator will at each visit assess 
the subject’s compliance by evaluating the glycaemic control, adherence to the visit schedule and 
completion of the subject’s diaries. If a subject is found to be non-compliant the investigator will 
remind the subject of the importance of following the instructions given including taking the trial 
products as prescribed.
7.8
Concomitant medication 
Any medication other than the trial products that the subject is receiving at the time of the first visit 
or receives during the trial must be recorded along with:
!
Trade name or generic name
!
Indication
!
Dates of administration including start and stop dates
!
Only applicable for anti-diabetic medication: start date of current dose and total daily dose
Changes in concomitant medication must be recorded at each visit; this includes changes of dose for 
subjects treated with OADs. If a change is due to an AE/SAE then this must be reported according 
to Section 9.2.
7.9
Treatment after the end of the trial
When discontinuing trial products the subject should be transferred to a suitable marketed product 
at the discretion of the investigator.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
26 of 68
8
Discontinuation/Withdrawal criteria 
The subject may be discontinued at any time during the trial at the discretion of the investigator for 
safety, behavioural, compliance or administrative reasons. 
A subject may also withdraw consent at any time at his/her own request.
If a subject is discontinued or withdraws consent, the investigator must ask the subject if he/she is 
willing, as soon as possible, to have assessment performed according to Visit 39 and phone contact 
P40. See the flowchart Section 2 for data to be collected.
8.1
Discontinuation from trial
The subject must be discontinued from trial, if the following applies:
1. Included in the trial in violation of the inclusion/exclusion/run-in exclusion criteria or 
randomised in violation of the randomisation criteria
2. Pregnancy
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
5. Initiation of bolus insulin treatment, GLP-1 receptor agonists or other diabetes medication(s) 
for more than 14 continuous days.
6. Initiating use of real time CGM or FGM other than use specified by protocol
The primary reason for discontinuation of trial must be specified in the end-of-trial form in the 
CRF, and final drug accountability must be performed. 
A treatment discontinuation session must be made in the IWRS.
8.2
Withdrawal from the trial
Final drug accountability must be performed even if the subject is not able to come to the trial site. 
A treatment discontinuation session must be made in the IWRS. 
If a subject withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the investigator must document this in the medical record.
If the subject withdraws consent, Novo Nordisk may retain and continue to use any data collected 
before such a withdrawal of consent.
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where 
the reasons are obtained, the primary reason for withdrawal must be specified in the end of trial 
form in the CRF.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
27 of 68
8.2.1
Replacement of subjects
Subjects who discontinue trial or withdraw from trial will not be replaced.
8.3
Lost to follow-up
A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the trial site. 
The following actions must be taken if a subject fails to return to the trial site for a required visit:
!
The site must attempt to contact the subject and reschedule the missed visit as soon as 
possible and counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in the 
trial.
!
Before a subject is deemed lost to follow-up, the investigator must make every effort to 
regain contact with the subject (where possible, at least three telephone calls and, if 
necessary, a certified letter to the subject's last known mailing address or local equivalent 
methods). These contact attempts should be documented in the subject's source document.
!
Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the trial with a primary reason of lost to 'follow -up' and discontinued in IWRS. 
9
Trial assessments and procedures
!
Trial procedures and their timing are summarised in the flowchart. 
!
Informed consent must be obtained before any trial related activity, see Appendix 3.
!
All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria. 
!
The investigator will maintain a screening log to record details of all subjects screened and 
to confirm eligibility or record reason for screen failure, as applicable.
!
At screening, subjects will be provided with a card stating that they are participating in a 
trial and giving contact details of relevant trial site staff. 
!
Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct. 
!
Compliance with the FGM requirement should be evaluated at Visit 3 after the run-in period 
and after each maintenance period to ensure collection of data to perform analysis of the 
primary endpoint.
!
Review of completed diaries, PRO questionnaires and laboratory reports must be 
documented either on the documents or in the subject's source documents. If clarification of 
entries or discrepancies in the diaries or PRO questionnaires is needed, the subject must be 
questioned and a conclusion made in the subject's source documents. Care must be taken not 
to bias the subject.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
28 of 68
!
Repeat samples may be taken for technical issues and unscheduled samples or assessments 
may be taken for safety reasons. Please refer to Appendix 2 for further details on laboratory 
samples.
9.1
Efficacy assessments 
Planned time points for all efficacy assessments are provided in the flowchart.
9.1.1
FGM 
As indicated in the flow chart in Section 2, all subjects will have FGM profiles generated 3 times 
during the trial.
The FGM system used in this trial will be the FreeStyle Libre Pro system which consists of two 
parts: 
!
the sensor, applied on the back of the subjects’ upper arm
!
the reader, a hand held device kept at site and used to download data stored on the sensor
The sensor is pre-calibrated during manufacturing and requires no fingerstick calibration during 
use. The sensor measurements performed in the interstitial fluid are automatically calibrated to 
plasma equivalent glucose values, which will be shown on the display of the reader upon download 
of sensor data. 
The FGM readings will be blinded to the subject as the reader will be kept at site. Upon download 
of FGM data at site, the investigator or delegated staff should review the FGM data for safety 
considerations taking into account all information detailed in the Operator’s manual.
The FGM values generated should not be used for insulin dose titration.
9.1.1.1
FGM Reader setting
Each site will receive 2 readers; one to activate all subjects’ sensors and download of their data and 
one as backup. 
The FGM reader must be set up before use. The set up includes:
!
date and time setting
!
entry of the target glucose range. The range 70-180 mg/dL (3.9–10.0 mmol/L) should be 
used.
Time and date as well as level of battery should be verified each time the reader is used. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
29 of 68
9.1.1.2
Fitting and removal of the FGM sensor
Before the first fitting visit (Visit 2), subjects’ eligibility must be confirmed.
The sensor must be applied on the back of the upper arm of the subjects, using the sensor applicator 
as described in the Operator’s manual. When applied, a thin, flexible and sterile fibre is inserted just 
under the skin of the subjects, allowing the measurement of glucose concentration in the interstitial 
fluid. 
The sensor must be activated by holding the site reader within 4cm (1.5inch) of the sensor. 
Successful start of the sensor must be checked as described in the Operator’s manual.
The sensor will store the subject’s glucose readings every 15 minutes for up to 14 days. 
For further information on preparing, fitting, and removal of the FGM system, please refer to the 
Operator’s manual.
If a subject withdraws consent during one of the FGM periods, a site visit must be scheduled in 
order to remove the sensor and download data to the reader. 
9.1.1.3
Duration of FGM periods
The sensor has an in-use period of 14 days and will automatically stop recording data 14 days after 
insertion and activation.
As the data accuracy may vary during the first 24 hours after sensor fitting, the FGM data from the 
1st day (24h) of each sensor period will be excluded from analysis. 
Subjects must aim to use the sensor for 14 days in-use period. 
In cases where the sensor is dislodged prematurely, the subject must be fitted with a new 
sensor as soon as possible. The cumulative number of day’s data collected by the sensors must 
be a minimum of 14 days.
Additional fitting visit at site will not be considered an unscheduled visit. 
For example: if the first sensor falls off 8 days after fitting, the subject then must be fitted with a 
second sensor to be worn for at least 6 days to obtain a total of 14 days of data.
At Visit 21 and Visit 39, it must be confirmed that a total of 14 days of data have been 
recorded, before subjects are switched to the other IMP or end treatment.
9.1.1.4
Wearing of the FGM sensor
Before each FGM periods, subjects must be instructed to follow the recommendations and 
limitations described in the Operator’s manual and user guide while wearing the FGM sensor.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
30 of 68
Subjects must be instructed to remove the FGM sensor prior to any X-ray, Computerised 
Tomography (CT) scan, high-frequency electrical heat (diathermy) treatment or magnetic resonance 
imaging (MRI).
The FGM periods should be conducted on days representing the subject’s normal daily life. 
Before each FGM period, investigator or site staff should evaluate with subjects if planned activities 
would require the FGM assessments to be postponed (e.g. vacations, unusual strenuous exercise, 
overseas travel etc.).
FGM periods should not be planned across local daylight saving clock shifts to avoid major 
impact on time related endpoints, and subjects must be instructed to avoid overnight travel 
across time zones while wearing the FGM.
9.1.1.5
Transfer of FGM data
Data stored on the sensor must be downloaded at the site by holding the reader within 4cm (1.5inch) 
of the sensor. Data on the reader device must then be uploaded to the provided FGM Software 
program that allows upload of the FGM data from the reader, following the instructions from the 
user guide provided to sites.
The upload will be documented by the system directly.
The following information must be recorded and transferred into the eCRF for every FGM period:
!
Serial number of the FGM sensor
!
Sensor activation date and time
!
Sensor removal date and time
The investigator or delegated staff must ensure that at least 14 days of data have been recorded 
according to Section 9.1.1.3. This can be done either on the reader or after upload of FGM data.
The FGM data can be shared with the subject after each FGM period. In case several sensors are 
used within each FGM period, the data should only be shared once when all needed data have been 
downloaded from the reader, according to Section 9.1.1.3. 
9.1.2
Self-measured plasma glucose 
Subjects must be instructed to perform pre-breakfast SMPG on the two days prior to, and on the day 
of the visit/contacts, from Visit 3 to Visit 39. 
The BG meter provided by Novo Nordisk must be used for the measurements required in the 
protocol. 
Subjects must also be instructed in how to transfer the results of the SMPG values into the diaries.
The record of each SMPG value should include date and value. All data from the diary must be 
transcribed into the CRF during or following the site contact. If obtained via phone and a 
discrepancy is later detected, the values in the CRF must be corrected.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
31 of 68
Occasional review by the investigator of the BG meter values stored in the memory of the BG meter 
and correct reporting of these in the diary is advised in order to ensure adequacy of the data reported 
in the trial database. 
9.1.3
Clinical efficacy laboratory assessments
All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in 
accordance with the flowchart (see Section 2) and the laboratory manual.
9.2
Adverse events
The definitions of AEs and SAEs can be found in Appendix 4.
The investigator is responsible for detecting, documenting, recording and following up on events 
that meet the definition of an AE or SAE.
As the safety profile of the investigational medicinal products are well characterized, in this trial the 
selective safety data collection7 will be limited to:
!
SAEs
!
AEs leading to permanent discontinuation of the IMP
!
Medication errors related to trial products
!
Pregnancies
The investigator must ensure that the above will be recorded in the CRF in a timely manner.
9.2.1
Time period and frequency for collecting AE and SAE information
All events meeting the definition of an SAE (see Appendix 4), AEs leading to permanent 
discontinuation of the IMP, pregnancies and medication errors related to trial products must be 
collected and reported. 
These events will be collected from the first trial-related activity after obtaining informed consent 
and until the end of trial visit, at the time points specified in the flowchart. All SAEs will be 
recorded and reported to Novo Nordisk or designee within 24 hours of investigator’s knowledge of 
the SAE, as indicated in Appendix 4. The investigator must submit any updated SAE data to Novo 
Nordisk within 24 hours of it being available.
After a subject has completed the trial, the investigators are not obligated to actively seek for safety 
collection in former trial subjects. However, if the investigator learns of any SAE, including a 
death, at any time after a subject has been discontinued from/completed the trial, and the 
investigator considers the event to be possibly/probably related to the investigational trial product or 
trial participation, the investigator must promptly notify Novo Nordisk.
The method of recording, evaluating and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 4.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
32 of 68
Medications errors related to trial products require additional data collection via a specific event 
form. 
Timelines for reporting of AEs are listed in Figure 2.
AE identified
AE form ≤  24 hours
SIF ≤5 calendar days
Sign off ≤ 7 calendar days
Is the AE serious or 
non-serious?
AE form
Is the AE listed as 
requiring a Specific Event 
Form to be completed?
Non-serious
Serious
No additional action
No
Specific event form
For SAE:
≤14 calendar days
Yes
Timelines are from the awareness of an AE .
Queries and follow-up requests to be resolved ≤14 calendar days.
AE: Adverse Events, SAE: Serious Adverse Events, SIF: Safety Information Form
Figure 2 Decision tree for determining the event type and the respective forms to complete 
with associated timelines
9.2.2
Method of detecting AEs and SAEs
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-
leading verbal questioning of the subject is the preferred method to inquire about events.
9.2.3
Follow-up on AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, or if the event 
is otherwise explained (e.g. chronic condition) or the subject is lost to follow-up (as defined in 
Section 8.3). Further information on follow-up procedures is given in Appendix 4.
9.2.4
Regulatory reporting requirements for SAEs
Prompt notification by the investigator to Novo Nordisk of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects and the safety of a trial 
product under clinical investigation are met. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
33 of 68
Novo Nordisk has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a trial product under clinical investigation. Novo Nordisk 
will comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC, and investigators.
Investigator safety reports must be prepared for SUSARs according to local regulatory requirements 
and Novo Nordisk policy and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing a SAE or other specific safety 
information (e.g. summary or listing of SAEs), from Novo Nordisk will review and then file it 
along with the investigator's brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
9.2.5
Cardiovascular and death events
Not applicable.
9.2.6
Disease-related events and/or disease-related outcomes not qualifying as an AE or 
SAE
Not applicable.
9.2.7
Pregnancies and associated adverse events
Details of pregnancies in female subjects will be collected after the first-trial-related activity after 
obtaining informed consent and until pregnancy’s outcome and the new-born infant is one month of 
age.
If a pregnancy is reported in female subjects, the investigator should inform Novo Nordisk within 
14 calendar days of learning of the pregnancy and should follow the procedures outlined in and 
Figure 3 and Appendix 5. 
Pregnancy outcome should be documented in the subject's medical record. Abnormal pregnancy 
outcome (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies and ectopic 
pregnancy) is considered an SAE.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
34 of 68
Maternal form 1b
≤14 calendar days after birth
Maternal form 1a
≤14 calendar days
After birth/
termination 
of pregnancy
No additional 
action
Normal outcome 
Maternal form 2 ≤14 calendar days
Paternal form*1 ≤14 calendar days
Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 9.1.
Prior to 
birth or 
pregnancy 
termination 
For female subjects
Figure 3 Decision tree for determining the forms to complete with associated timelines for 
pregnancy
9.2.8
Medical device incidents (including malfunctions)
Not applicable.
9.2.9
Technical complaints
Technical complaints will be collected for all trial products listed on the technical complaint form..
The investigator must assess whether a technical complaint is related to an AE. The definitions and 
reporting process for technical complaints can be found in Appendix 6.
9.3
Treatment of overdose
The overdose must be reported as a medication error. Refer to Section 9.2.1 for further details.
In the event of an overdose, the investigator should closely monitor the subject for overdose-related 
AE/SAE and laboratory abnormalities until clinical recovery.
Decisions regarding dose interruptions or modifications will be made by the investigator based on 
the clinical evaluation of the subject.
For more information on overdose, also consult the current version of the IDeg investigator's 
brochure18 and SmPC of Insulin IGlar 100U/mL (Lantus®)14.
9.4
Safety assessments 
Planned time points for all safety assessments are provided in the flowchart Section 2.
A concomitant illness is any illness that is present at the start of the trial or found as a result of a 
screening procedure or other trial procedures performed before exposure to trial product. 
Medical history is a medical event that the subject has experienced in the past. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
35 of 68
Diabetes history and related complications should be reported separately in the diabetes 
history/complication form.
In case of an abnormal and clinically significant finding, the investigator must record the finding on 
the Medical History/Concomitant Illness form if it is present at screening. Any new finding 
fulfilling the AE definition (see Appendix 4) during the trial and any clinically significant 
worsening from baseline (Visit 2)  must be reported as an AE or SAE (see Section 9.2) if these 
events fulfilling the selective safety reporting requirements specified in Section 9.2.
9.4.1
Physical examinations
!
A physical examination will include assessments of:
!
Head, Ears, Eyes, Nose, Throat and Neck
!
Respiratory System
!
Cardiovascular System
!
Musculoskeletal System
!
Central and Peripheral Nervous System
!
Skin 
!
Body measurements will also be measured and recorded as specified in the flowchart.
!
Body weight should be measured in kilogram (kg) or pounds (lb) without coat and 
shoes wearing only light clothing. Body weight will be recorded to one decimal.
!
Height should be assessed without shoes. Height is measured in inches or 
centimetres at Visit 1 and recorded to the nearest whole number
!
From the body weight and height the BMI will be calculated in the eCRF.
!
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
9.4.2
Vital signs
!
Pulse rate as well as diastolic and systolic blood pressure will be assessed.
!
Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for 
the subject in a quiet setting without distractions (e.g. television, cell phones).
!
Blood pressure at screening will consist of 3 diastolic and systolic blood pressure 
measurements with intervals of at least 1 minute. All three readings must be entered in the 
eCRF and the average of the 3 blood pressure readings will be calculated in the eCRF. At 
the subsequent visits, the blood pressure should only be measured once.
!
Blood pressure and pulse measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available.
9.4.3
Clinical safety laboratory assessments
All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in 
accordance with the laboratory manual and the flowchart in Section 2.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
36 of 68
9.4.4
Eye Examination 
Subjects with uncontrolled and potentially unstable diabetic retinopathy or maculopathy are not 
eligible as this indicates retinopathy that has recently progressed to a level that requires intervention 
or is approaching intervention, but has yet to be brought under control. 
Results of an eye examination performed by an ophthalmologist, or another suitably qualified 
health care provider must be available and evaluated by the investigator before run-in (Visit 2) to 
assess eligibility. The eye examination should be performed as a fundus photography (e.g. 2-field 
60 degree or better, colour or red-free) or by slit-lamp biomicroscopy examination (e.g. using a pre-
corneal or corneal contact lens examination) and performed with pharmacologically dilated pupils.
If the subject had such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the results of that examination. The examination must 
be repeated before run-in (Visit 2) if the subject has experienced worsening of visual function since 
the last examination. If the applicable eye examination was performed before the subject signed the 
informed consent form, it must be documented that the reason for performing the examination was 
not related to this trial.
9.4.5
Pharmacokinetics 
Not applicable.
9.4.6
Pharmacodynamics
Not applicable.
9.4.7
Genetics
Not applicable.
9.4.8
Biomarkers
Not applicable.
9.5
Insulin dose
During the trial, starting at the randomisation visit (Visit 3), subjects must be instructed to report 
date and dose of basal insulin in the diaries on the two days prior to, and on the day of the 
visit/contacts, from Visit 3 to Visit 39. 
The recommended insulin doses will be calculated based on recommendations from the Titration 
Guideline (see Appendix 8) as described in Section 7.3. The investigator must record the following 
in the eCRF, for each treatment period:
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
37 of 68
!
First date, dose and injection time of trial product
!
Last date, dose and injection time of trial product
9.6
Health economics – PRO questionnaires
The Patient Reported Outcome (PRO) questionnaires are to be completed by the subject without 
assistance of the site personnel. Review of the PRO questionnaires must be documented either on 
the document and/or in the subject’s medical record. If clarification of entries is needed, the subject 
must be questioned and a conclusion made in the subject’s medical record. Care must be taken not 
to bias the subject. 
Following PRO questionnaires must be completed according to the flowchart (see Section 2):
!
Treatment related impact measure for diabetes device (TRIM-DD)
!
Diabetes Pen Experience Measure (DPEM)
Data will be summarized by item and visit by pooling the two treatment arms.
The rationale for the PRO assessment is to collect data for psychometric validation of the newly 
developed DPEM questionnaire. The psychometric analyses will examine reliability, 
responsiveness, and validity of the DPEM questionnaire. Data from the TRIM-D questionnaire data 
will be used in the psychometric analysis, to show that data from the DPEM questionnaire 
correlates as hypothesized. All results will be published and reported in the DPEM questionnaire 
development dossier.
10 Statistical considerations 
10.1
Sample size determination 
The sample size calculation is based on the primary objective for the primary estimand and the 
primary endpoint of the trial, and is performed as a paired-sample calculation in terms of the mean 
and standard deviation of the within pair difference within the PP using the paired t-test. Only one 
previous Novo Nordisk trial using CGM has had a similar design: NN1250-3874 comparing IDeg
and IGlar 100U/mL in 24 T1DM subjects using a cross-over design. Regarding time in glycaemic 
target range (70-180 mg/dL) during the full 24 hours of the day, the within pair difference between 
IDeg and IGlar 100U/mL had a mean of 0.39 hours and a standard deviation of 2.3. Two previous 
Novo Nordisk studies have used CGM in T2DM subjects in parallel arm designs, NN1250-3579 
and NN1250-3668. However, CGM technology used in those two T2DM trials is outdated 
compared to the devices used in the current trial, and they are therefore deemed irrelevant as to 
guidance on expected difference between the two treatments in this trial. The results from the 
NN1250-3874 trial are used for sample size calculation despite the differences from the present 
trial, i.e. indication and length of maintenance treatment. A conservative standard deviation of 2.6 is 
used. To detect a mean difference of 0.39 with 85% power with a standard deviation of 2.6 based on 
a paired t-test and 1:1 randomisation requires 401 subjects included in the PP. See Table 3 for 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
38 of 68
sample sizes based on a range of standard deviation and for mean differences of 0.39 and 0.5 
respectively.
In the SWITCH 2 trial (NN1250-3998), which had a similar cross-over trial design, 72.1% 
(721/1000) of the screened subjects were randomised and 80% (580/721) completed treatment in 
both periods. Part of the drop-out in SWITCH 2 was due to the inconvenience caused by the blinded 
vial and syringes which is not an issue in the present trial. Also, SWITCH 2 was considerably 
longer than the current trial with 16 weeks long maintenance periods. Furthermore, the current trial 
has a run-in period ensuring familiarity with and acceptance of the FGM device. We therefore 
assume that only 15% will not complete both periods on treatment and, thus, that 85% will end in 
PP. Hence, we will randomise 1:1 a total of 401/0.85=472 subjects (236 in each sequence) and we 
expect to screen app. 472/0.7=674 subjects. According to the ADA criteria, 70% of readings, 
equivalent to 10 days, should be available for a subject to be included in the analysis. We expect 
that nearly all completers will live up to this and therefore do not adjust the number of subjects 
needed to account for this.
Table 3 Sample size and power for various standard deviations and effects 
Effect
SD
0.39
0.50
2.0
239
146
2.3
315
192
2.6
401
245
Sample size is computed for 1:1 randomisation and 85% power. SD: standard deviation.
10.2
Definition of analysis sets
The full analysis set  is all subjects randomised at Visit 3. The safety analysis set is all subjects that 
are randomised and treated with at least one dose of trial drug after randomisation. The PP analysis 
set consists of subjects that stay on assigned treatment until and complete FGM assessment at visits 
21 and 39 respectively.
10.3
Statistical analyses
If necessary, a statistical analysis plan may be written in addition to the protocol, including a more 
technical and detailed elaboration of the statistical analyses. The statistical analysis plan will be 
finalised before database lock. 
10.3.1
Primary endpoint
The primary endpoint is the percentage of time spent in glycaemic target range (70-180 mg/dL (3.9-
10.0 mmol/L), both inclusive) during the 2-week maintenance period. The FreeStyle Libre Pro 
device stores four measurements per hour and a subject with complete data will contribute with 
14*24*4=1344 measurements from each 2-week period. The analysis will discard data from the 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
39 of 68
first 24 hours as per communication with the vendor and so subjects with complete data will 
contribute with 13*24*4=1248 glucose recordings. The number of recorded measurements may be 
smaller for various reasons for subjects in the PP analysis set. Following ADA criteria we will 
demand that at least 70% of two weeks FGM measurements, corresponding to 10 days of FGM 
data, must be available for subjects to be included in the analysis. The percentage of time spent in 
glycaemic target range will be calculated as the number of recorded measurements in glycaemic 
target range (70-180 mg/dL (3.9-10.0 mmol/L), both inclusive) divided by the total number of 
recorded measurements.
The primary estimand will be estimated by the primary endpoint analysed in a linear mixed model 
with treatment and period as fixed effects, subject as a random effect and with an unstructured 
residual variance matrix.
Using the unblinded data and before DBL, visual tools will be used to determine whether the data, 
including the primary endpoint, are normally distributed. If it is then found that the data are not 
normal, an appropriate transformation will be performed and this will be documented in a SAP or 
the DBL minutes.
Superiority of IDeg OD compared to IGlar 100U/mL OD with respect to percentage of time spent in 
glycaemic target range will be considered confirmed if non-inferiority is confirmed and the lower 
limit of the two-sided 95% confidence interval of the difference (IDeg OD - IGlar 100U/mL OD) is 
entirely above zero or equivalently if the p-value for the one-sided test of 
H0: D ≤ 0% against HA: D > 0%
is smaller than 2.5%, where D is the estimated mean difference of time spent in glycaemic target 
range (IDeg OD - IGlar 100U/mL OD). As such, a fixed hierarchical testing procedure will be 
applied, which will effectively adjust for multiple testing.
Non-inferiority will be evaluated by comparing the lower limit of the t wo-sided 95% confidence 
interval for the difference between IDeg and IGlar 100U/mL to a non-inferiority margin of 0.2h/24h 
(0.83%). If the lower CI limit is above -0.83%, non-inferiority will be considered established.
Missing data due to intercurrent events such as trial discontinuation are not relevant since the 
primary estimand is based on the PP analysis set.
A sensitivity analysis will be performed to account for heteroscedasticity due to a varying number 
of FGM readings within the 70% demand. The primary endpoint will be transformed using inverse 
variance weighting. Specifically, the primary endpoint will be multiplied by a weight calculated as 
the inverse of the square root of the total number of FGM readings.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
40 of 68
An additional sensitivity analysis will be performed where all subjects who have FGM readings for 
at least seven consecutive days will be included. Inverse variance weighting will be performed as 
described previously.
10.3.2
Secondary endpoints
Supportive secondary endpoints
Percentage of time spent in tight glycaemic target range (70-140 mg/dL (3.9-7.8 mmol/L), both 
inclusive is calculated in the same way as the primary endpoint using the relevant ranges. A 
sensitivity analysis using the inverse of the square root of the number of FGM readings as inverse 
variance weights to account for heteroscedasticity due to a varying number of FGM readings will be 
performed.
Percentage of time spent in nocturnal glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both 
inclusive, in the nocturnal period (00:01 am–05:59 am both inclusive) will be calculated in the same 
way as the primary endpoint but only using readings with a time stamp in the relevant time period. 
A sensitivity analysis using the inverse of the square root of the number of FGM readings in the 
relevant time period as inverse variance weights to account for heteroscedasticity due to a varying 
number of FGM readings will be performed.
All the supportive secondary endpoints regarding time spent in target range are analysed and tested 
in the same model as the primary endpoint, i. e. one sided tests of the mean difference favouring 
IDeg must be statistically significantly different from zero at the 0.025 level to support superiority.
As stated in Section 9.1.1.4, sites are instructed not to initiate FGM monitoring periods that will 
contain daylight saving clock shifts. During data analysis it will be checked if this rule is obeyed, 
and the length of both the entire day in question in general, and the nocturnal period in question in 
particular will be adjusted equivalently when it is not. For example, if a subject is under FGM 
monitoring in the US on 11-MAR-2018 the nocturnal period will start at 00:01AM and end at 04:59 
(nominal sensor time) instead of 05:59. In the data analysis one hour will be added to the recorded 
time points from 02:00 and onwards. In practise then, 11-MAR-2018 will consist of no more than 
23h of FGM readings, and the nocturnal period of no more than 4h and 58 minutes of FGM 
readings. If on the other hand a subject is under FGM monitoring on 04-NOV-2018 in the US one 
hour will be deducted from the time recorded time points. This will then consist of no more than 25 
hours of FGM readings, and the nocturnal period of no more than 6h and 58 minutes of FGM 
readings. The hour between 01:00-02:00 on 04-NOV will be represented twice in the data, and to 
separate them an auxiliary variable stating if a time reading is in the daylight saving period or not 
will be added to all FGM readings.
The mean glucose levels (mg/dL and mmol/L) will be calculated as the mean of the FGM glucose 
levels and analysed by models and test equivalent to the primary endpoint. A sensitivity analysis 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
41 of 68
using the inverse of the square root of the total number of FGM readings as inverse variance 
weights will be performed to account for heteroscedasticity due to a varying number of readings pr 
subject pr. period.
Mean HbA1c values will be analysed using a similar model as compared to the primary endpoint, 
but only a single two-sided test for statistically significant differences between IDeg and IGlar 
100U/mL will be performed.
10.3.3
Exploratory endpoints
Glycaemic variability will be calculated as the standard deviation (mg/dL and mmol/L) and 
coefficient of variation (%) of the FGM glucose levels during the 2-week maintenance treatment 
periods. Both will be analysed and tested with models and tests equivalent to the primary endpoint.
Mean insulin dose in international units  is calculated as the mean dose over the maintenance 
treatment periods for each subject. It will be analysed and tested using models and tests equivalent 
to the primary endpoint.
Percentage of time spent in the hypoglycaemic alert range (54-69 mg/dL (3.0-3.8 mmol/l), both 
inclusive) and percentage of time spent in the clinically significant hypoglycaemic range (<54 
mg/dL (<3.0 mmol/L)) are calculated in the same way as the primary endpoint using the relevant 
ranges. A sensitivity analysis using the inverse of the square root of the number of FGM readings as 
inverse variance weights to account for heteroscedasticity due to a varying number of FGM 
readings will be performed.
All the exploratory endpoints regarding time in range are analysed and tested in the same model as 
the primary endpoint, i. e. one sided tests of the mean difference favouring IDeg must be 
statistically significantly different from zero at the 0.025 level to support superiority.
Number of hypoglycaemic episodes <54 mg/dL (<3.0 mmol/L) for at least 15 minutes and number 
of hypoglycaemic episodes <54mg/dL (<3.0 mmol/L) for at least 15 minutes in the nocturnal period 
(00:01-05:59 AM, both inclusive) will be counted as follows: At least two consecutive FGM 
glucose readings (i.e., readings that follow each other continuously in time) in the specified range 
are counted as a hypoglycaemic episode. Two hypoglycaemic episodes must be separated by at 
least 15 minutes above the hypoglycaemic range, equivalent to 2 consecutive FGM readings above 
the relevant hypoglycaemic range to be counted as two or more episodes instead of one. For the 
nocturnal episodes, only FGM readings in the relevant period will be used. Person years of 
exposure (PYE) will be calculated as
PYE=(N_FGM*15 minutes)/(365.25 days/year*(24 hours)/day*(60 minutes)/hour)
where N_FGM is the total number FGM readings in the relevant period. The number of 
hypoglycaemic episodes will be analysed using a negative binomial regression with treatment and 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
42 of 68
period as fixed effects, subject as a normally distributed random effect and the log(PYE) as an 
offset. A p-value smaller than 0.025 for the one sided test of the rate ratio in favour of IDeg will be 
considered as support for superiority of IDeg over IGlar 100U/mL. If this model does not converge, 
a Poisson regression model will be fitted.
10.4
Pharmacokinetic and/or pharmacodynamic modelling
Not applicable
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
43 of 68
11 References
1.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 
Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 
Kidney Int Suppl. 2013;3(1):1-150.
2.
Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 
awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic 
frequency and associated symptoms. Diabetes Care. 1995;18(4):517-22.
3.
International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 
mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of 
the American Diabetes Association and the European Association for the Study of Diabetes. 
Diabetes Care. 2017;40(1):155-7.
4.
Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, et al. Role of Continuous 
Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technol 
Ther. 2017;19(7):391-9.
5.
Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of 
Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes 
Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 
2017;317(4):371-8.
6.
Novo, Nordisk A/S. Investigator's Brochure, insulin  ( Tresiba®), project NN1250 (edition 
14). 19 Mar 2018.
7.
Food and Drug Administration CaC. Guidance for Industry. Determining the Extent of 
Safety Data Collection Needed in Late-Stage Premarket and Postapproval Clinical 
Investigations. February 2016.
8.
Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res. 2005;36(3):197-209.
9.
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, et al. Targeting 
intensive glycaemic control versus targeting conventional glycaemic control for type 2 
diabetes mellitus. Cochrane Database Syst Rev. 2013(11):CD008143.
10.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. 
Update to a position statement of the American Diabetes Association and the European 
Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-42.
11.
Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. 
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With 
Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017;318(1):45-56.
12.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin 
degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
44 of 68
with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-
507.
13.
Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. 
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-
year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 
2012;35(12):2464-71.
14.
Sanofi-Aventis Groupe. Lantus®   (insulin glargine), EU Summary of Product 
Characteristics (SmPC). 01 Mar 2017.
15.
Novo Nordisk A/S. Lantus® - U.S. Label information. 2015.
16.
Hoss U, Budiman ES, Liu H, Christiansen MP. Feasibility of Factory Calibration for 
Subcutaneous Glucose Sensors in Subjects With Diabetes. J Diabetes Sci Technol. 
2014;8(1):89-94.
17.
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-40.
18.
Novo Nordisk A/S. Investigator's Brochure, insulin degludec (11th edition). December 
2015.
19.
World Medical Association. Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, 
Fortaleza, Brazil. 1 Oct 2013.
20.
ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2), Current 
Step 4 version. 09 Nov 2016.
21.
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org.
22.
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
23.
U.S. Food and Drug Administration. Food and Drug Administration Amendments Act of 
2007 as amended by the Final Rule "Clinical Trials Registration and Results Information 
Submission". 21 September 2016.
24.
The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
45 of 68
products for human use, article 11. Official Journal of the European Communities. 01 May 
2001.
25.
The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
46 of 68
12 Appendices
Abbreviations and Trademarks
Appendix 1
ADA
American Diabetes Association
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BG
blood glucose
CGM
continuous glucose monitoring
(e)CRF
(electronic) case report form
CTR
clinical trial report
DUN
dispensing unit number
eGFR
estimated glomerular filtration rate 
FDA
U.S. Food and Drug Administration
FDAAA
FDA Amendments Act
FGM
flash glucose monitoring
FSH
follicle-stimulating hormone 
GCP
Good Clinical Practice
GLP-1
glucagon-like peptide-1 
HbA1c
glycated haemoglobin
hCG
human chorionic gonadotropin 
HRT
hormone replacement therapy
IB
investigator’s brochure
ICH
International Council for Harmonisation
ICMJE
International Committee of Medical Journal Editors 
IEC
independent ethics committee
IMP
investigational medicinal product
IRB
institutional review board
IUD
intrauterine device
IUS
intrauterine hormone-releasing system 
IWRS
interactive web response system
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
47 of 68
LSFT 
last subject first treatment 
NIMP
non-investigational medical product
OAD(s)
oral anti-diabetic drug(s)
OD
once daily
PCD
primary completion date
PP
per protocol
PRO
patient reported outcome
PYE 
person years of exposure 
SAE
serious adverse event
SAP
statistical analysis plan
SMPC
summary of product characteristics
SMPG
self-measured plasma glucose
SUSAR
suspected unexpected serious adverse reaction
T2DM
type 2 diabetes mettilus
TMM
trial materials manual
WOCBP
woman of child bearing potential
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
48 of 68
Clinical laboratory tests.
Appendix 2
!
The tests detailed in Table 4 and Table 5 will be performed by the central laboratory.
!
Additional tests may be performed at any time during the trial as determined necessary by 
the investigator or required by local regulations. Only laboratory samples specified in the 
protocol should be sent to the central laboratory for analysis; if additional laboratory 
sampling is needed, e.g. to follow up on AEs, this must be done at a local laboratory.
!
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the 
laboratory standard operating procedures. Such data will not be transferred to the trial 
database, but abnormal values will be reported to the investigator. 
!
The investigator must review all laboratory results for concomitant illnesses and AEs.
!
Laboratory samples will be destroyed after analysis on an ongoing basis.
Table 4 Protocol-required effect laboratory assessments
Laboratory assessments
Parameters
Glucose metabolism 
!
HbA1c
Table 5 Protocol-required safety laboratory assessments
Laboratory assessments
Parameters
Biochemistry1
!
Alanine Aminotransferase (ALT) 
!
Albumin
!
Alkaline phosphatase
!
Aspartate Aminotransferase (AST)
!
Creatinine
!
Potassium
!
Sodium
!
Bilirubin
Pregnancy Testing
!
Serum or urine human chorionic gonadotropin (hCG) pregnancy test (for 
WOCBP)
Other tests
!
eGFR calculated by the central laboratory based on the creatinine value using the 
CKD-EPI equation
Notes :
1Details of required actions for increased liver parameters are given in Appendix 4 (Hy’s Law)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
49 of 68
Trial governance considerations
Appendix 3
1) Regulatory and ethical considerations
This trial will be conducted in accordance with the protocol and with the following:
!
Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki19 and applicable ICH Good Clinical Practice (GCP) Guideline20
!
Applicable laws and regulations
!
The protocol, informed consent form, investigator’s brochure (as applicable) and other 
relevant documents (e.g. advertisements), must be submitted to an IRB/IEC and reviewed 
and approved by the IRB/IEC before the trial is initiated.
!
Regulatory authorities will receive the clinical trial application, protocol amendments, 
reports on SAEs, and the clinical trial report according to national requirements.
!
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate 
safety hazard to trial subjects.
!
Before a trial site is allowed to start screening subjects, written notification from Novo 
Nordisk must be received.
!
The investigator will be responsible for:
o
providing written summaries of the status of the trial annually or more frequently in 
accordance with the requirements, policies, and procedures established by the 
IRB/IEC and/or regulatory authorities
o
notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures
o
providing oversight of the conduct of the trial at the site and adherence to 
requirements of  ICH guidelines, the IRB/IEC, and all other applicable local 
regulations
o
ensuring submission of the clinical trial report (CTR) synopsis to the IRB/IEC.
2) Financial disclosure
Investigators and subinvestigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial.
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
50 of 68
3) Informed consent process
!
The investigator or his/her representative will explain the nature of the trial to the subject 
and answer all questions regarding the trial.
!
The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial. 
!
Subjects must be informed that their participation is voluntary.
!
Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines20, Declaration of Helsinki19 and the 
IRB/IEC or trial site.
!
The medical record must include a statement that written informed consent was obtained 
before any trial related activity and the date when the written consent was obtained. The 
authorised person obtaining the informed consent must also sign and date the informed 
consent form before any trial related activity.
!
The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the task of informing to a medically qualified person, in 
accordance with local requirements.
!
Subjects must be re-consented to the most current version of the informed consent form(s) 
during their participation in the trial.
!
A copy of the informed consent form(s) must be provided to the subject
4) Information to subjects during trial
The site will be offered a communication package for the subject during the conduct of the trial. 
The package content is issued by Novo Nordisk. The communication package will contain written 
information intended for distribution to the subjects. The written information will be translated and 
adjusted to local requirements and distributed to the subject at the discretion of the investigator. The 
subject may receive a “welcome to the trial letter” and a “thank you for your participation letter” 
after completion of the trial. Further the subject may receive other written information during the 
trial. 
All written information to subjects must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for approval or notification according to local regulations.
5) Data protection
!
Subjects will be assigned a 6-digit unique identifier, a subject number which will remain the 
same throughout the trial. Each site is assigned a 3-digit number and all subject numbers 
will start with the site number. Any subject records or datasets that are transferred to Novo 
Nordisk will contain the identifier only; subject names or any information which would 
make the subject identifiable will not be transferred.
!
The subject and any biological material obtained from the subject will be identified by 
subject number, visit number and trial ID. Appropriate measures such as encryption or 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
51 of 68
leaving out certain identifiers will be enforced to protect the identity of subjects as required 
by local, regional and national requirements, for Canada please see Appendix 7. 
!
The subject must be informed that his/her personal trial related data will be used by Novo 
Nordisk in accordance with local data protection law. The disclosure of the data must also 
be explained to the subject. 
!
The subject must be informed that his/her medical records may be examined by auditors or 
other authorised personnel appointed by Novo Nordisk, by appropriate IRB/IEC members, 
and by inspectors from regulatory authorities.
6) Committee structure
Novo Nordisk safety committee
Novo Nordisk will constitute an internal IDeg safety committee to perform ongoing safety 
surveillance.
7) Publication policy
The information obtained during the conduct of this trial is considered confidential, and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the trial product. All information supplied by Novo Nordisk in connection with this 
trial shall remain the sole property of Novo Nordisk and is to be considered confidential 
information.
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial.
The information obtained during this trial may be made available to other investigators who are 
conducting other clinical trials with the trial product, if deemed necessary by Novo Nordisk. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this trial to researchers who require access for research projects studying the same 
disease and/or trial product studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One investigator will be appointed by Novo Nordisk to review and sign the clinical trial report 
(signatory investigator) on behalf of all participating investigators.
Communication of results
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes publication of a manuscript in a peer-reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by other means. 
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are reached, for example when the clinical trial report is available. This 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
52 of 68
includes the right not to release the results of interim analyses, because the release of such 
information may influence the results of the entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property.
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
content of any publication, both the investigators’ and Novo Nordisk opinions will be fairly and 
sufficiently represented in the publication.
Authorship
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, analysis or interpretation of data to report the results in one 
or more publications.
Authorship of publications should be in accordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by the International 
Committee of Medical Journal Editors21.
All authors will be provided with the relevant statistical tables, figures, and reports needed to 
evaluate the planned publication. 
Where required by the journal, the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by the journal. 
Site-specific publication(s) by investigator(s)
For a multicentre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should always reference the primary manuscript of the trial.
Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database.
Individual investigators will have their own research subjects' data, and will be provided with the 
randomisation code after results are available.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
53 of 68
8) Dissemination of clinical trial data
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. It will also 
be disclosed according to other applicable requirements such as those of the International 
Committee of Medical Journal Editors (ICMJE)22, the Food and Drug Administration Amendment 
Act (FDAAA)23, European Commission Requirements24 25  and other relevant recommendations or 
regulations. If a subject requests to be included in the trial via the Novo Nordisk e-mail contact at 
these web sites, Novo Nordisk may disclose the investigator’s contact details to the subject. As a 
result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations.
The Primary Completion Date (PCD) is the last assessment of the primary endpoint, and is for this 
trial Last Subject First Treatment (LSFT) + 36 weeks corresponding to visit 39. If the last subject is 
withdrawn early, the PCD is considered the date when the last subject would have completed visit 
39. The PCD determines the deadline for results disclosure at clinicaltrials.gov according to 
FDAAA.
9) Data quality assurance
Case Report Forms (CRFs)
!
Novo Nordisk or designee is responsible for the data management of this trial including 
quality checking of the data.
!
All subject data relating to the trial will be recorded on electronic CRFs unless transmitted 
electronically to Novo Nordisk or designee (e.g. laboratory and FGM data). The investigator 
is responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF. 
!
eCRF will be used in this trial, as well as diaries to capture subject reported data
!
The following will be provided as paper CRFs: 
!
Pregnancy forms
!
The following will be provided as paper CRFs to be used when access to the CRF is revoked 
or the CRF is temporarily unavailable: 
!
AE forms 
!
Safety information forms 
!
Technical complaint forms (also to be used to report complaints that are not subject 
related, e.g. discovered at trial site before allocation) 
!
Corrections to the CRF data may be made by the investigator or the investigator’s delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the 
old and the new data, identification of the person entering the data, date and time of the 
entry and reason for the correction. If corrections are made by the investigator’s delegated 
staff after the date when the investigator signed the CRF, the CRF must be signed and dated 
again by the investigator.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
54 of 68
!
The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to 
Novo Nordisk for data verification and validation purposes. 
Monitoring
!
The investigator must permit trial-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents (original 
documents, data and records). Direct access includes permission to examine, analyse, verify 
and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If 
the electronic medical record does not have a visible audit trail, the investigator must 
provide the monitor with signed and dated printouts. In addition the relevant trial site staff 
should be available for discussions at monitoring visits and between monitoring visits (e.g. 
by telephone). 
!
Trial monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorised site personnel are accurate, complete and verifiable from source 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is 
being conducted in accordance with the currently approved protocol and any other trial 
agreements, ICH GCP, and all applicable regulatory requirements.
!
Monitoring will be conducted using a risk based approach including risk assessment, 
monitoring plans, centralised monitoring (remote assessment of data by Novo Nordisk) and 
visits to trial sites. 
!
Monitors will review the subject’s medical records and other source data e.g. the diaries and 
PROs, to ensure consistency and/or identify omissions compared to the CRF. 
Protocol compliance
Deviations from the protocol should be avoided. If deviations do occur, the investigator must 
inform the monitor and the implications of the deviation must be reviewed and discussed.
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the CRF or via listings from the trial database. 
10) Source documents
!
All data entered in the CRF must be verifiable in source documentation other than the CRF.
!
The original of the completed diaries and PROs must not be removed from the trial site, 
unless they form part of the CRF and a copy is kept at the site. 
!
Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the trial site.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
55 of 68
!
Data reported on the paper CRF or entered in the electronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must 
be explained. The investigator may need to request previous medical records or transfer 
records. Also, current medical records must be available. 
!
It must be possible to verify subject’s medical history in source documents such as subject’s 
medical record.
!
The investigator must document any attempt to obtain external medical information by 
noting the date(s) when information was requested and who was contacted.
!
Definition of what constitutes source data can be found in a source document agreement at 
each trial site. There will only be one source document defined at any time for any data 
element.
!
The database hosted by the supplier is considered source data for the laboratory and FGM 
data during the trial.
11) Retention of clinical trial documentation
!
Records and documents, including signed informed consent forms, pertaining to the conduct 
of this trial must be retained by the investigator for 15 years after end of trial unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of Novo Nordisk. No 
records may be transferred to another location or party without written notification to Novo 
Nordisk. 
!
The investigator must be able to access his/her trial documents without involving Novo 
Nordisk in any way. If applicable, electronic CRF and other subject data will be provided in 
an electronic readable format to the investigator before access is revoked to the systems and 
electronic devices supplied by Novo Nordisk. Site-specific CRFs and other subject data (in 
an electronic readable format or as paper copies or prints) must be retained by the trial site. 
If the provided electronic data  is not readable during the entire storage period, the 
investigator can request a new copy. A copy of all data will be stored by Novo Nordisk.
!
Subject’s medical records must be kept for the maximum period permitted by the hospital, 
institution or private practice
12) Trial and site closure
Novo Nordisk reserves the right to close the trial site or terminate the trial at any time for any 
reason at the sole discretion of Novo Nordisk. If the trial is suspended or terminated, the 
investigator must inform the subjects promptly and ensure appropriate therapy and follow-up. The 
investigator and/or Novo Nordisk must also promptly inform the regulatory authorities and 
IRBs/IECs and provide a detailed written explanation.
Trial sites will be closed upon trial completion. A trial site is considered closed when all required 
documents and trial supplies have been collected and a trial site closure visit has been performed.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
56 of 68
The investigator may initiate trial site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a trial site by Novo Nordisk or investigator may include but are not 
limited to:
!
failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, Novo Nordisk procedures or GCP guidelines
!
inadequate recruitment of subjects by the investigator
!
discontinuation of further trial product development.
13) Responsibilities
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects. 
A qualified physician, who is an investigator or a subinvestigator for the trial, must be responsible 
for all trial-related medical decisions. 
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification 
code list must be kept in a secure locked facility so that no unauthorized persons can get access to 
the data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires) a 
new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
57 of 68
14) Indemnity statement 
Novo Nordisk carries product liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence. 
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the trial or by persons for whom the said site or investigator are 
responsible. 
Novo Nordisk accepts liability in accordance with: 
!
The Civil Code and the Pharmaceutical Law dated 6 September 2001 (uniform version 
Journal of Laws of 2008 No.45 item 271 with amendments) for Poland, please see 
Appendix 7.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
58 of 68
Adverse events: definitions and procedures for 
Appendix 4
recording, evaluation, follow-up, and reporting
AE definition
!
An AE is any untoward medical occurrence in a clinical trial subject that is temporally associated with the use 
of a medicinal product, whether or not considered related to the medicinal product.
!
An AE can be any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or 
disease (new or exacerbated) temporally associated with the use of a medicinal product.
Events meeting the AE definition
!
Any abnormal laboratory test results or safety assessments, including those that worsen from baseline, 
considered clinically significant in the medical and scientific judgment of the investigator.
!
Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency 
and/or intensity of the condition.
!
Signs, symptoms or the clinical sequelae of a suspected drug-drug interaction.
!
Signs, symptoms or the clinical sequelae of a suspected overdose of trial product regardless of intent.
Events NOT meeting the AE definition 
!
Pre-existing conditions, anticipated day-to-day fluctuations of pre-existing conditions, including those 
identified during screening or other trial procedures performed before exposure to trial product. 
Note: pre-existing conditions should be recorded as medical history/concomitant illness.
!
Pre-planned procedures, unless the condition for which the procedure was planned has worsened from the first 
trial related activity after the subject has signed the informed consent.
Definition of an SAE
An SAE is an AE that fulfils at least one of the following criteria:
!
Results in death
!
Is life-threatening
The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at 
the time of the event. It does not refer to an event which hypothetically might have caused death, if it were more 
severe.
!
Requires inpatient hospitalisation or prolongation of existing hospitalisation
!
Hospitalisation signifies that the subject has been detained at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs 
hospitalisation or fulfils any other serious criteria, the event is serious. When in doubt as to whether 
“hospitalisation” occurred or was necessary, the AE should be considered serious.
!
Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is 
not considered an AE.
Note:

Hospitalisations for administrative, trial related and social purposes do not constitute AEs 
and should therefore not be reported as AEs or SAEs.

Hospital admissions for surgical procedures, planned before trial inclusion, are not 
considered AEs or SAEs.
!
Results in persistent disability/incapacity
!
The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
59 of 68
!
This definition is not intended to include experience of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained 
ankle), which may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption.
!
Is a congenital anomaly/birth defect
!
Important medical event:
!
Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in 
other situations. This includes important medical events that may not be immediately life-threatening or 
result in death or hospitalisation, but may jeopardise the subject or may require medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition. These events should 
usually be considered serious and reported as SAEs using the important medical event criterion.
!
The following adverse events must always be reported as SAEs using the important medical event 
criterion, if no other seriousness criteria are applicable:

suspicion of transmission of infectious agents via the trial product. 

risk of liver injury defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 x 
UNL and total bilirubin >2 x UNL, where no alternative aetiology exists (Hy's law).
Description of AEs requiring additional data collection (via specific event form) 
Medication error:
A medication error concerning trial products is defined as:
!
Administration of wrong drug.
Note: Use of wrong DUN is not considered a medication error unless it results in a confirmed administration of 
wrong drug. 
!
Wrong route of administration, such as intramuscular instead of subcutaneous. 
!
Administration of an overdose with the intention to cause harm, misuse or abuse of trial product.
!
Accidental administration of a lower or higher dose than intended: That is a dose lower or higher than 20%' of 
the prescribed/intended dose; however, the administered dose must deviate from the intended dose to an extent 
where clinical consequences for the trial subject were likely to happen as judged by the investigator, although 
they did not necessarily occur.
AE and SAE recording
!
All SAEs, AEs leading to discontinuation of trial, medication errors and AEs in connection with pregnancies, 
must be recorded by the investigator on an AE form. The investigator will attempt to establish a diagnosis of 
the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
!
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital 
progress notes, laboratory and diagnostics reports) related to the event.
!
For all non-serious AEs the applicable forms should be signed when the event is resolved or at the end of the 
trial at the latest. For sign-off of SAE related forms refer to “SAE reporting via paper CRF” later in this 
section.
!
Novo Nordisk products used as concomitant medication: if an AE is considered to have a causal relationship 
with a Novo Nordisk marketed product used as concomitant medication in the trial, it is important that the 
suspected relationship is reported to Novo Nordisk, e.g. in the alternative aetiology section on the safety 
information form. Novo Nordisk may need to report this adverse event to relevant regulatory authorities.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
60 of 68
Assessment of severity
The investigator will assess intensity for each event reported during the trial and assign it to one of the following 
categories: 
!
Mild: An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with 
everyday activities.
!
Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities.
!
Severe: An event that prevents normal everyday activities. 
Note: Severe is a category used for rating the intensity of an event; and both an AE and SAE can be assessed 
as severe. An event is defined as ‘serious’ when it meets at least one of the outcomes described in the 
definition of an SAE and not when it is rated as severe.
Assessment of causality
The investigator is obligated to assess the relationship between trial product and the occurrence of each AE/SAE.
Relationship between an AE/SAE and the relevant trial product(s) should be assessed as: 
!
Probable - Good reason and sufficient documentation to assume a causal relationship.
!
Possible - A causal relationship is conceivable and cannot be dismissed.
!
Unlikely - The event is most likely related to aetiology other than the trial product.
Alternative aetiology, such as underlying disease(s), concomitant medication, and other risk factors, as well as the 
temporal relationship of the event to trial product administration will be considered and investigated.
The investigator should use the current version of investigator’s brochure for IDeg and (or) SmPC for comparator for 
the assessment. For each AE/SAE, the investigator must document in the medical records that he/she has reviewed the 
AE/SAE and has provided an assessment of causality with alternative aetiology whenever applicable.
There may be situations in which an SAE has occurred and the investigator has minimal information to include in the 
initial report. However, it is important that the investigator always makes an assessment of causality for every 
event before the initial transmission of the SAE data.
The investigator may change his/her opinion of causality in light of follow-up information and send a follow-up report 
with the updated causality assessment.
The causality assessment is one of the criteria used when determining regulatory reporting requirements.
Final outcome
The investigator will select the most appropriate outcome:
!
Recovered/resolved: The subject has fully recovered, or by medical or surgical treatment the condition has 
returned to the level observed at the first trial-related activity after the subject signed the informed consent.
!
Recovering/resolving: The condition is improving and the subject is expected to recover from the event. This 
term is only applicable if the subject has completed the trial or has died from another AE.
!
Recovered/resolved with sequelae: The subject has recovered from the condition, but with lasting effect due 
to a disease, injury, treatment or procedure. If a sequelae meets an SAE criterion, the AE must be reported as 
an SAE.
!
Not recovered/not resolved: The condition of the subject has not improved and the symptoms are unchanged 
or the outcome is not known.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
Status:
Final
Page:
61 of 68
!
Fatal: This term is only applicable if the subject died from a condition related to the reported AE. Outcomes of
other reported AEs in a subject before he/she died should be assessed as “recovered/resolved”,
“recovering/resolving”, “recovered/resolved with sequelae” or “not recovered/not resolved”. An AE with a
fatal outcome must be reported as an SAE.
!
Unknown: This term is only applicable if the subject is lost to follow-up.
Follow-up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as 
medically indicated or as requested by Novo Nordisk to elucidate the nature and/or causality of the AE or SAE as fully 
as possible (e.g. severe hypersensitivity reactions). This may include additional laboratory tests (e.g. skin prick test) or 
investigations, histopathological examinations, or consultation with other health care professionals.
New or updated information will be recorded in the CRF.
SAE reporting via electronic CRF
! Relevant forms (AE and safety information form) must be completed in the CRF.
! For reporting and sign-off timelines, see box below.
! If the CRF is unavailable for more than 24 hours, then the site will use the paper AE form and if the CRF is
unavailable for more than 5 calendar days then the site will use the safety information form (see box below).
! The site will enter the SAE data into the CRF as soon as it becomes available, see 9.2.1.
! After the trial is completed at a given site, the CRF will be decommissioned to prevent the entry of new data or
changes to existing data. If a site receives a report of a new SAE from a subject or receives updated data on a
previously reported SAE after CRF decommission, then the site can report this information on a paper AE and safety
information form (see box below) or to Novo Nordiskby telephone.
SAE reporting via paper CRF
!
Relevant CRF forms (AE and safety information form) must be forwarded to Novo Nordisk either by fax, e-
mail or courier.
!
Initial notification via telephone is acceptable, although it does not replace the need for the investigator to
complete the AE and safety information form within the designated reporting time frames (as illustrated in
Figure 2):
!
AE form within 24 hours.
!
Safety information form within 5 calendar days.
!
Both forms must be signed within 7 calendar days.
Contact details for SAE reporting can be found in the investigator trial master file.
Reporting of AEs for Non-Novo Nordisk medical devices provided by Novo Nordisk for use in the trial
Reporting of AEs on:
!
FreeStyle Libre Pro device and supplies
!
BG meter device and supplies.
All complaints (including AEs) should be reported directly to the manufacturer. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
62 of 68
Contraceptive guidance and collection of pregnancy 
Appendix 5
information
It must be recorded in the CRF whether female subjects are of childbearing potential. 
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. 
Women in the following categories are not considered WOCBP
1. Premenarcheal 
2. Premenopausal female with one of the following:
!
Documented hysterectomy
!
Documented bilateral salpingectomy
!
Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of subject’s medical records, 
medical examination or medical history interview.
3. Postmenopausal female
!
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high Follicle Stimulating Hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or Hormonal Replacement Therapy (HRT). However, in the absence of 12 
months of amenorrhea, a single FSH measurement is insufficient. 
!
Females on HRT and whose menopausal status is in doubt will be required to use one of the 
non-hormonal highly effective contraception methods if they wish to continue their HRT 
during the trial. Otherwise, they must discontinue HRT to allow confirmation of 
postmenopausal status before trial enrolment.
Contraception guidance
Female subjects:
Female subjects of childbearing potential are eligible to participate if they agree to use methods of 
contraception consistently and correctly as described in table(s) below:
Table 6 Highly effective contraceptive methods
Highly effective contraceptive methods that are user dependent a
Failure rate of <1% per year when used consistently and correctly.
!
Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of 
ovulation b 
!
oral 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
63 of 68
Table 7 Acceptable effective contraceptive methods
Acceptable effective contraceptive methodsa
Failure rate of >1% per year when used consistently and correctly
!
Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mode of action.
!
Male or female condom with or without spermicide 
!
Cap, diaphragm or sponge with spermicide 
Note: 
aTypical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for subjects participating in clinical trials. 
Pregnancy testing
!
WOCBP should only be included after a negative highly sensitive serum pregnancy test.
!
Additional urine pregnancy testing should be performed at monthly intervals during the 
treatment period, if required locally.
!
Pregnancy testing should be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.
!
intravaginal 
!
transdermal
Progestogen only hormonal contraception associated with inhibition of ovulation
!
oral 
!
injectable
Highly effective methods that are user independent a
Implantable progestogen only hormonal contraception associated with inhibition of ovulation b
!
Intrauterine Device (IUD)
!
Intrauterine hormone-releasing System (IUS)
!
Bilateral tubal occlusion
Vasectomised partner 
A vasectomised partner is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used.
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the trial product. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject.
Notes: 
aTypical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for subjects participating in clinical trials. 
bHormonal contraception may be susceptible to interaction with the trial product, which may reduce the efficacy of the 
contraceptive method. In this case, two highly effective methods of contraception should be utilised during the 
treatment period and for at least 7 days after the last dose of trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
64 of 68
Collection of pregnancy information 
Female subjects who become pregnant 
!
Investigator will collect pregnancy information on any female subject, who becomes 
pregnant while participating in this trial.
!
Information will be recorded on the appropriate form and submitted to Novo Nordisk within 
14 calendar days of learning of a subject's pregnancy.
!
Subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow-up information on subject and neonate, which will be forwarded to Novo 
Nordisk. Generally, follow-up will not be required for longer than 1 month beyond the 
delivery date.
!
Any termination of pregnancy will be reported, regardless of foetal status (presence or 
absence of anomalies) or indication for procedure.
!
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy will be reported as an AE or SAE. 
!
A spontaneous abortion is always considered to be an SAE and will be reported as such.
!
Any SAE occurring as a result of a post-trial pregnancy which is considered 
possibly/probably related to the trial product by the investigator will be reported to Novo 
Nordisk as described in Appendix 4 . While the investigator is not obligated to actively seek 
this information in former subjects, he or she may learn of an SAE through spontaneous 
reporting. 
Any female subject who becomes pregnant while participating in the trial will discontinue trial 
product. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
Status:
Final
Page:
65 of 68
Technical complaints: Definition and procedures for 
Appendix 6
recording, evaluation, follow-up and reporting
Technical complaint definition
!
A technical complaint is any written, electronic or oral communication that alleges product (medicine or
device) defects. The technical complaint may be associated with an AE, but does not concern the AE itself.
Examples of technical complaints:
!
Problems with the physical or chemical appearance of trial products (e.g. discoloration, particles or
contamination).
!
Problems with packaging material including labelling.
!
Problems related to medical devices (e.g. to the injection mechanism, dose setting mechanism, push button or
interface between the pen-injector and the needle).
Time period for detecting technical complaints 
!
All technical complaints, which occur from the time of receipt of the product at trial site until the time of the
last usage of the product, must be collected for products predefined on the technical complaint form.
Reporting of technical complaints to Novo Nordisk
Contact details (fax, e-mail and address) for Customer Complaint Center –refer to Attachment I
Technical complaints must be reported on a separate technical complaint form:
1.
One technical complaint form must be completed for each affected DUN
2.
If DUN is not available, a technical complaint form for each batch, code or lot number must be completed
Timelines for reporting of technical complaints to Novo Nordisk
The investigator must complete the technical complaint form in the CRF within 24 hours if related to an SAE. All other 
technical complaints with or without associated AEs within 5 calendar days. If the CRF is unavailable or when 
reporting a technical complaint that is not subject related, the information must be provided on a paper form by fax, e-
mail or courier to Customer Complaint Center, Novo Nordisk, within the same timelines as stated above. When the 
CRF becomes available again, the investigator must enter the information on the technical complaint form in the CRF.
Follow-up of technical complaints 
The investigator is responsible for ensuring that new or updated information will be recorded on the originally 
completed form. 
Collection, storage and shipment of technical complaint samples
The investigator must collect the technical complaint sample and all associated parts that were packed in the same DUN 
and notify the monitor within 5 calendar days of obtaining the sample at trial site. The sample and all associated parts 
must be sent as soon as possible to Customer Complaint Center, Novo Nordisk, together with a copy of the completed 
technical complaint form. The technical complaint sample should contain the batch, code or lot number and, if 
available, the DUN. If the technical complaint sample is unobtainable, the reason must be stated on the technical 
complaint form. If several samples are shipped in one shipment, the sample and the corresponding technical complaint 
form should be kept together.
Storage of the technical complaint sample must be done in accordance with the conditions prescribed for the product.
Reporting of technical complaints for Novo Nordisk products not included in technical complaint form
Technical complaints on Novo Nordisk products not included in the technical complaint form should be reported to 
local Novo Nordisk affiliate with a reference to trial ID.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
66 of 68
Country-specific requirements 
Appendix 7
!
For Poland: Novo Nordisk carries liability for the trial exclusively in the scope defined by 
the applicable laws and in particular by the Civil Code and the Pharmaceutical Law dated 6 
September 2001 (uniform version Journal of Laws of 2008 No.45 item 271 with 
amendments). In order to support potential claims for liability attributable to the Trial, Novo 
Nordisk and investigator are covered by Insurance Policy issued according to applicable 
Polish law.
!
For Slovakia: It is necessary that the Trial Sponsor covers all costs for treatment of the 
disease studied. It is necessary to cover the whole diabetes medication, payment for insulin, 
OADs listed in Inclusion criteria no. 5 and rescue medication, if used.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
67 of 68
Titration guideline
Appendix 8
Titration guidelines have been developed, providing recommended dose adjustments at different PG 
levels to ensure that subjects receive an optimal treatment. However, it is recognised that insulin 
treatment should be individualised and the specific titration algorithms may not be applicable in 
certain clinical situations. Hence, it is important that other information, such as symptoms of 
hypo/hyperglycaemia, previous response to dose adjustments, other glucose measurements and 
other indicators of the subject’s level of glycaemic control, is taken into consideration when 
decisions on dosing are made. The investigator is responsible for the treatment of the subjects and 
can therefore overrule the guidelines to avoid safety hazards.
Initiation of trial products
IGlar 100U/mL and IDeg should be injected subcutaneously into the thigh, upper arm (deltoid area) 
or the abdomen. The chosen region should be the same throughout the trial for each trial products. 
Rotation of injection sites within a given region is recommended.
Both IMPs should be taken once daily any time of the day, but at the same time every day.
At randomisation (Visit 3) subjects will initiate treatment according to local label for the relevant 
IMP. At cross-over (Visit 21) the subjects should switch according to local label for the relevant 
IMP.
Dose adjustment of trial products during the trial
After randomisation the insulin dose will be evaluated and possibly adjusted once weekly by the 
investigator in connection with the scheduled visits/phone contacts during the titration periods. 
The dose adjustment will be based on the mean of three fasting SMPG values measured on two 
days prior to titration and on the day of the visit/contacts according to Table 8. If one of the SMPG 
values is below target (<3.9 mmol/L or 70 mg/dL) then dose adjustment will be based on the lowest 
SMPG values according to Table 9.
If one or more SMPGs values are missing, the adjustment should be performed on the remaining 
SMPG value(s).
Table 8 Increase of insulin dose
Mean pre-breakfast SMPG values
Increase of basal insulin
dose
mmol/L
mg/dL
U
3.9 – 5.0
70 – 90
No adjustment
5.1 – 7.0
91 – 126
+ 2
7.1 – 8.0
127 – 144
+ 4
8.1 – 9.0
145 – 162
+ 6
> 9.0
> 162
+ 8
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
01 June 2018
1RYR1RUGLVN
Trial ID: NN1250-4419
Version:
3.0
     
Status:
Final
     
Page:
68 of 68
Table 9 Reduction of insulin dose
Lowest pre-breakfast SMPG value
Reduction of basal insulin dose
mmol/L
mg/dL
U
3.1 – 3.8
56 – 69
- 2
<3.1
< 56
- 4
Deviations from the algorithm
It is recommended that the algorithm is followed. However, it is also important that the decision to 
adjust insulin doses is based on all relevant information. A reason for deviating from the algorithm 
should be entered into the eCRF by the investigator as applicable.
Data surveillance
Surveillance of titration data will be performed centrally by Novo Nordisk in an unbiased or, if 
possible, a blinded manner. The data will be reviewed and significant changes from the titration 
algorithm will be followed up. 
It is important that data regarding dose titration is entered into the applicable system. If delays 
occur, action cannot be taken in due time before the subject’s next site visit/phone contact. The aim 
is to reduce the time periods in which a subject may receive suboptimal treatment.
The titration data should be reviewed by Novo Nordisk within 24 hours (on workdays). The 
reviewer may contact the investigator by e-mail or phone to clarify reasons for deviation or to 
request entry of missing data. When the investigator receives an inquiry, a response should be 
received at Novo Nordisk within 24 hours (on workdays).
In addition, Novo Nordisk will monitor changes in HbA1c. Novo Nordisk may visit or phone sites 
to discuss progress in glycaemic control and titration of individual subjects.
CONFIDENTIAL


Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staff
&21),'(17,$/
'DWH
1RYR1RUGLVN
9HUVLRQ
6WDWXV
,QVXOLQGHJOXGHF7UHVLED
7ULDO,'11
&OLQLFDO7ULDO5HSRUW
$SSHQGL[
0D\

)LQDO
CONFIDENTIAL

SAP_001.pdf: 
Cover Page for Statistical Analysis Plan  
 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT03687827 
Sponsor trial ID: 
NN1250-4419 
Official title of study: 
A randomised, cross-over, open-label, multi-centre trial 
comparing the effect of insulin degludec and insulin glargine 
100U/mL, with or without OADs in subjects with type 2 
diabetes using flash glucose monitoring 
Document date 
04 May 2020 
 


/LQN
/LVWRIFRQWHQWV
6WDWLVWLFDODQDO\VLVSODQ
&21),'(17,$/
'DWH
1RYR1RUGLVN
9HUVLRQ
6WDWXV
,QVXOLQGHJOXGHF7UHVLED
7ULDO,'11
&OLQLFDO7ULDO5HSRUW
$SSHQGL[
0D\

)LQDO
'RFXPHQWDWLRQRIVWDWLVWLFDOPHWKRGV
CONFIDENTIAL
Redacted VWDWLVWLFDODQDO\VLVSODQ 
Includes redaction of personal identifiable information only. 
. 


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI

6WDWLVWLFDO$QDO\VLV3ODQ
7ULDO,'11

7LWOH$UDQGRPLVHGFURVVRYHURSHQODEHOPXOWLFHQWUHWULDOFRPSDULQJWKHHIIHFWRI
LQVXOLQGHJOXGHFDQGLQVXOLQJODUJLQH8P/ZLWKRUZLWKRXW2$'VLQVXEMHFWVZLWKW\SH
GLDEHWHVXVLQJIODVKJOXFRVHPRQLWRULQJ

6:,7&+352

$XWKRU

%LRVWDWLVWLFV,QVXOLQDQG'HYLFHV
7KLVFRQILGHQWLDOGRFXPHQWLVWKHSURSHUW\RI1RYR1RUGLVN1RXQSXEOLVKHGLQIRUPDWLRQFRQWDLQHGKHUHLQPD\EH
GLVFORVHGZLWKRXWSULRUZULWWHQDSSURYDOIURP1RYR1RUGLVN$FFHVVWRWKLVGRFXPHQWPXVWEHUHVWULFWHGWRUHOHYDQW
SDUWLHV
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI

7DEOHRIFRQWHQWV
7DEOHRIFRQWHQWV 
/LVWRIDEEUHYLDWLRQV 
 
,QWURGXFWLRQ 
 
7ULDOLQIRUPDWLRQ 
 
6FRSHRIWKHVWDWLVWLFDODQDO\VLVSODQ 
 
6WDWLVWLFDOFRQVLGHUDWLRQV 
 
6DPSOHVL]HGHWHUPLQDWLRQ 
 
'HILQLWLRQRIDQDO\VLVVHWV 
 
3ULPDU\HQGSRLQW 
 
6HFRQGDU\HQGSRLQWV 
 
([SORUDWRU\HQGSRLQWV 
 
&KDQJHVWRWKHVWDWLVWLFDODQDO\VHVSODQQHGLQWKHSURWRFRO 
 
&RQWULEXWLRQWRSHUSURWRFRODQDO\VLVVHW 
 
3UHVHQWDWLRQRIWHVWKLHUDUFK\ 
 
6SHFLILFDWLRQRIZHLJKWVIRUSULPDU\HQGSRLQW 
 
)XUWKHUVSHFLILFDWLRQRIZHLJKWVIRUSULPDU\HQGSRLQW 
 
6HQVLWLYLW\DQDO\VLVIRUSULPDU\HQGSRLQW 
 
6SHFLILFDWLRQRIZHLJKWVIRUVHFRQGDU\HQGSRLQW3HUFHQWDJHRIWLPHVSHQWLQWLJKW
JO\FDHPLFWDUJHWUDQJH 
 
)XUWKHUVSHFLILFDWLRQRIZHLJKWVIRUVHFRQGDU\HQGSRLQW3HUFHQWDJHRIWLPHVSHQWLQ
QRFWXUQDOJO\FDHPLFWDUJHWUDQJH 
 
&ODULILFDWLRQRIVHFRQGDU\HQGSRLQW 
 
)XUWKHUVSHFLILFDWLRQRIZHLJKWVIRUVHFRQGDU\HQGSRLQWPHDQJOXFRVHOHYHOV 
 
&ODULILFDWLRQRI8/24DQG//24LQ)*0GDWD 
 
&ODULILFDWLRQRIH[SORUDWRU\HQGSRLQW 
 
6SHFLILFDWLRQRIZHLJKWVIRUH[SORUDWRU\HQGSRLQW3HUFHQWDJHRIWLPHVSHQWLQWKH
K\SRJO\FDHPLFDOHUWUDQJH 
 
5HIHUHQFHV 

CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


/LVWRIDEEUHYLDWLRQV
$'$
$PHULFDQ'LDEHWHV$VVRFLDWLRQ
&*0
FRQWLQXRXVJOXFRVHPRQLWRULQJ
)*0
IODVKJOXFRVHPRQLWRULQJ
+E$F
JO\FDWHGKDHPRJORELQ
//24
ORZHUOLPLWRITXDQWLILFDWLRQ
2$'V
RUDODQWLGLDEHWLFGUXJV
2'
RQFHGDLO\
33
SHUSURWRFRO
3<(
SHUVRQ\HDUVRIH[SRVXUH
6$3
VWDWLVWLFDODQDO\VLVSODQ
7'0
W\SHGLDEHWHVPHWWLOXV
8/24
XSSHUOLPLWRITXDQWLILFDWLRQ
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI



,QWURGXFWLRQ

7ULDOLQIRUPDWLRQ
2EMHFWLYHVHVWLPDQGDQGHQGSRLQWV
3ULPDU\VHFRQGDU\DQGH[SORUDWLYHREMHFWLYHV
7KHSULPDU\REMHFWLYHLVWRFRPSDUHWKHHIIHFWRQJO\FDHPLFFRQWURORI,'HJYHUVXV,*ODU8P
LQDSRSXODWLRQRI7'0VXEMHFWVZLWKRUZLWKRXW2$'VXVLQJ)*0
(VWLPDQG
7KHSULPDU\HVWLPDQGLVWKHWUHDWPHQWGLIIHUHQFHEHWZHHQ,'HJDQG,*ODU8P/ZLWKUHVSHFWWR
SHUFHQWWLPHVSHQWLQJO\FDHPLFWDUJHWUDQJHIRUDOOUDQGRPLVHGVXEMHFWVWKDWFDQXVHWKH)*0
VHQVRUDQGDGKHUHWRDWOHDVWZHHNVRIWUHDWPHQWRQERWKLQVXOLQV$QLQWHUFXUUHQWHYHQWIRUWKH
SULPDU\HVWLPDQGLQFOXGHODFNRIHIIHFWIURPDQ\RIWKHLQVXOLQVOHDGLQJWRDQHHGIRULQLWLDWLRQRI
RWKHUGLDEHWHVPHGLFDWLRQV$VGHVFULEHGLQVHFWLRQLQWKHSURWRFROWUHDWPHQWLQWHQVLILFDWLRQ
PD\UHVXOWLQWULDOGLVFRQWLQXDWLRQ7KHSULPDU\HVWLPDQGZLOOKDQGOHWKHVHLQWHUFXUUHQWHYHQWVDV
ZLWKGUDZDOVDQGRQO\XVHGDWDIURPFRPSOHWHUV7KHSULPDU\HVWLPDQGLVWKHSULQFLSOHVWUDWXP
GLUHFWHIIHFWIRUWKHSRSXODWLRQRIFRPSOHWHUV
3ULPDU\HQGSRLQW
3HUFHQWDJHRIWLPHVSHQWLQJO\FDHPLFWDUJHWUDQJHPJG/±PPRO/ERWK
LQFOXVLYHGXULQJWKHZHHNPDLQWHQDQFHSHULRGXVLQJ)*09LVLWZHHNDQG9LVLW
ZHHN
6XSSRUWLYHVHFRQGDU\HQGSRLQWV
x
3HUFHQWDJHRIWLPHVSHQWLQWLJKWJO\FDHPLFWDUJHWUDQJHPJG/±PPRO/
ERWKLQFOXVLYHGXULQJWKHZHHNPDLQWHQDQFHSHULRGVXVLQJ)*09LVLWZHHN
DQG9LVLWZHHN
x
3HUFHQWDJHRIWLPHVSHQWLQQRFWXUQDOJO\FDHPLFWDUJHWUDQJHPJG/
PPRO/ERWKLQFOXVLYHLQWKHQRFWXUQDOSHULRGDP±DPERWKLQFOXVLYH
GXULQJWKHZHHNPDLQWHQDQFHSHULRGVXVLQJ)*09LVLWZHHNDQG9LVLW
ZHHN
x
+E$FDQGPPROPRODIWHUWZRZHHNVRIPDLQWHQDQFHSHULRGV9LVLWZHHN
DQG9LVLWZHHN
x
0HDQJOXFRVHOHYHOVPJG/DQGPPRO/GXULQJWKHZHHNPDLQWHQDQFHSHULRGVXVLQJ
)*09LVLWZHHNDQG9LVLWZHHN
([SORUDWRU\HQGSRLQWV
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


x
*O\FDHPLFYDULDELOLW\FDOFXODWHGDVVWDQGDUGGHYLDWLRQPJG/DQGPPRO/DQGFRHIILFLHQW
RIYDULDWLRQRIJOXFRVHOHYHOVGXULQJWKHZHHNPDLQWHQDQFHWUHDWPHQWXVLQJ
)*09LVLWZHHNDQG9LVLWZHHN
x
0HDQLQVXOLQGRVH,8GXULQJWKHZHHNPDLQWHQDQFHWUHDWPHQWSHULRG9LVLWZHHN
DQG9LVLWZHHN
x
3HUFHQWDJHRIWLPHVSHQWLQWKHK\SRJO\FDHPLDDOHUWUDQJH/HYHOPJG/
PPRO/ERWKLQFOXVLYHGXULQJWKHZHHNPDLQWHQDQFHSHULRGVXVLQJ)*09LVLW
ZHHNDQG9LVLWZHHN
x
3HUFHQWDJHRIWLPHVSHQWLQWKHFOLQLFDOO\VLJQLILFDQWK\SRJO\FDHPLFUDQJH/HYHO
PJG/PPRO/GXULQJWKHZHHNPDLQWHQDQFHSHULRGVXVLQJ)*09LVLW
ZHHNDQG9LVLWZHHN
x
1XPEHURIFOLQLFDOO\VLJQLILFDQWK\SRJO\FDHPLFHSLVRGHV/HYHOPJG/
PPRO/IRUDWOHDVWPLQXWHVGXULQJWKHZHHNPDLQWHQDQFHSHULRGVXVLQJ)*09LVLW
ZHHNDQG9LVLWZHHN
x
1XPEHURIFOLQLFDOO\VLJQLILFDQWK\SRJO\FDHPLFHSLVRGHV/HYHOPJG/
PPRO/IRUDWOHDVWPLQXWHVLQWKHQRFWXUQDOSHULRG$0ERWKLQFOXVLYH
GXULQJWKHZHHNPDLQWHQDQFHSHULRGVXVLQJ)*09LVLWZHHNDQG9LVLW
ZHHN
7ULDOGHVLJQ
7KLVWULDOLVDZHHNUDQGRPLVHGFURVVRYHURSHQODEHOPXOWLFHQWHUDFWLYHFRQWUROOHGWULDO
FRPSDULQJWKHHIIHFWRILQVXOLQ,'HJYHUVXVLQVXOLQ,*ODU8P/ZLWKRUZLWKRXW2$'VLQ
VXEMHFWVZLWKW\SHGLDEHWHVXVLQJIODVKJOXFRVHPRQLWRULQJ
7KHWULDOLQFOXGHVDVFUHHQLQJYLVLW9LVLWIROORZHGE\DZHHNUXQLQSHULRGIRUHOLJLELOLW\
DVVHVVPHQWLQUHJDUGVWRDGKHUHQFHWR)*0UHTXLUHPHQWV$WUDQGRPLVDWLRQ9LVLWHOLJLEOH
VXEMHFWVZLOOEHUDQGRPLVHGLQWRRQHRIWZRWUHDWPHQWSHULRGVUHFHLYLQJHLWKHU,'HJRU,*ODU
8P/(DFKWUHDWPHQWSHULRGFRQVLVWRIDZHHNWLWUDWLRQSHULRGIROORZHGE\DZHHNV
PDLQWHQDQFHSHULRGZKHUHVXEMHFWVZLOOZHDUWKH)UHH6W\OH/LEUH3UR6HQVRU$IWHUWKHILUVWWLWUDWLRQ
DQGPDLQWHQDQFHSHULRGWKHVXEMHFWZLOOVZLWFKWRWKHRWKHUWULDOSURGXFWZLWKGRVHDGMXVWPHQW
DFFRUGLQJWRORFDOODEHOSHUIRUPLQJWKHVDPHDVVHVVPHQWVDVLQWKHILUVWWUHDWPHQWSHULRGZHHN
WLWUDWLRQSHULRGIROORZHGE\DZHHNVPDLQWHQDQFHSHULRG
7KHIROORZXSSHULRGLVZHHN
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


)LJXUH
7ULDO'HVLJQ
)XUWKHUGHWDLOV

)RUIXUWKHUGHWDLOVRQWULDOGHVLJQDQGHQGSRLQWVSOHDVHVHHWKH11SURWRFROYHUVLRQ

6FRSHRIWKHVWDWLVWLFDODQDO\VLVSODQ
7KLV6$3LVEDVHGRQWKH11SURWRFROYHUVLRQ

6WDWLVWLFDOFRQVLGHUDWLRQV

6DPSOHVL]HGHWHUPLQDWLRQ
7KHVDPSOHVL]HFDOFXODWLRQLVEDVHGRQWKHSULPDU\REMHFWLYHIRUWKHSULPDU\HVWLPDQGDQGWKH
SULPDU\HQGSRLQWRIWKHWULDODQGLVSHUIRUPHGDVDSDLUHGVDPSOHFDOFXODWLRQLQWHUPVRIWKHPHDQ
DQGVWDQGDUGGHYLDWLRQRIWKHZLWKLQSDLUGLIIHUHQFHZLWKLQWKH33XVLQJWKHSDLUHGWWHVW2QO\RQH
SUHYLRXV1RYR1RUGLVNWULDOXVLQJ&*0KDVKDGDVLPLODUGHVLJQ11FRPSDULQJ,'HJ
DQG,*ODU8P/LQ7'0VXEMHFWVXVLQJDFURVVRYHUGHVLJQ5HJDUGLQJWLPHLQJO\FDHPLF
WDUJHWUDQJHPJG/GXULQJWKHIXOOKRXUVRIWKHGD\WKHZLWKLQSDLUGLIIHUHQFHEHWZHHQ
,'HJDQG,*ODU8P/KDGDPHDQRIKRXUVDQGDVWDQGDUGGHYLDWLRQRI7ZRSUHYLRXV
1RYR1RUGLVNVWXGLHVKDYHXVHG&*0LQ7'0VXEMHFWVLQSDUDOOHODUPGHVLJQV11
DQG11+RZHYHU&*0WHFKQRORJ\XVHGLQWKRVHWZR7'0WULDOVLVRXWGDWHG
FRPSDUHGWRWKHGHYLFHVXVHGLQWKHFXUUHQWWULDODQGWKH\DUHWKHUHIRUHGHHPHGLUUHOHYDQWDVWR
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


JXLGDQFHRQH[SHFWHGGLIIHUHQFHEHWZHHQWKHWZRWUHDWPHQWVLQWKLVWULDO7KHUHVXOWVIURPWKH
11WULDODUHXVHGIRUVDPSOHVL]HFDOFXODWLRQGHVSLWHWKHGLIIHUHQFHVIURPWKHSUHVHQW
WULDOLHLQGLFDWLRQDQGOHQJWKRIPDLQWHQDQFHWUHDWPHQW$FRQVHUYDWLYHVWDQGDUGGHYLDWLRQRILV
XVHG7RGHWHFWDPHDQGLIIHUHQFHRIZLWKSRZHUZLWKDVWDQGDUGGHYLDWLRQRIEDVHGRQ
DSDLUHGWWHVWDQGUDQGRPLVDWLRQUHTXLUHVVXEMHFWVLQFOXGHGLQWKH336HH7DEOHIRU
VDPSOHVL]HVEDVHGRQDUDQJHRIVWDQGDUGGHYLDWLRQDQGIRUPHDQGLIIHUHQFHVRIDQG
UHVSHFWLYHO\
7DEOH
6DPSOHVL]HDQGSRZHUIRUYDULRXVVWDQGDUGGHYLDWLRQVDQGHIIHFWV

'HILQLWLRQRIDQDO\VLVVHWV
7KHIXOODQDO\VLVVHWLVDOOVXEMHFWVUDQGRPLVHGDW9LVLW7KHVDIHW\DQDO\VLVVHWLVDOOVXEMHFWVWKDW
DUHUDQGRPLVHGDQGWUHDWHGZLWKDWOHDVWRQHGRVHRIWULDOGUXJDIWHUUDQGRPLVDWLRQ
7KH33DQDO\VLVVHWFRQVLVWVRIVXEMHFWVWKDWVWD\RQDVVLJQHGWUHDWPHQWXQWLODQGFRPSOHWH)*0
DVVHVVPHQWDWYLVLWVDQGUHVSHFWLYHO\&RPSOHWH)*0DVVHVVPHQWLVVSHFLILHGDVVXEMHFWV
KDYLQJDWOHDVWRIWZRZHHNV)*0PHDVXUHPHQWVSHUPDLQWHQDQFHSHULRG
PHDVXUHPHQWV)*0PHDVXUHPHQWVIURPWKHILUVWKRXUVRIHDFKILWWHGVHQVRUDUHGLVUHJDUGHG
$OOHQGSRLQWDQDO\VLVZLOOEHSHUIRUPHGRQWKH33DQDO\VLVVHW

3ULPDU\HQGSRLQW
7KHSULPDU\HQGSRLQWLVWKHSHUFHQWDJHRIWLPHVSHQWLQJO\FDHPLFWDUJHWUDQJHPJG/
PPRO/ERWKLQFOXVLYHGXULQJWKHZHHNPDLQWHQDQFHSHULRG7KH)UHH6W\OH/LEUH3UR
GHYLFHVWRUHVIRXUPHDVXUHPHQWVSHUKRXUDQGDVXEMHFWZLWKFRPSOHWHGDWDZLOOFRQWULEXWHZLWK
 PHDVXUHPHQWVIURPHDFKZHHNSHULRG7KHDQDO\VLVZLOOGLVFDUGGDWDIURPWKH
ILUVWKRXUVDVSHUFRPPXQLFDWLRQZLWKWKHYHQGRUDQGVRVXEMHFWVZLWKFRPSOHWHGDWDZLOO
FRQWULEXWHZLWK JOXFRVHUHFRUGLQJV7KHQXPEHURIUHFRUGHGPHDVXUHPHQWVPD\EH
VPDOOHUIRUYDULRXVUHDVRQVIRUVXEMHFWVLQWKH33DQDO\VLVVHW)ROORZLQJ$'$FULWHULDZHZLOO
GHPDQGWKDWDWOHDVWRIWZRZHHNV)*0PHDVXUHPHQWVFRUUHVSRQGLQJWRGD\VRI)*0
GDWDPXVWEHDYDLODEOHIRUVXEMHFWVWREHLQFOXGHGLQWKHDQDO\VLV7KHSHUFHQWDJHRIWLPHVSHQWLQ
JO\FDHPLFWDUJHWUDQJHZLOOEHFDOFXODWHGDVWKHQXPEHURIUHFRUGHGPHDVXUHPHQWVLQJO\FDHPLF
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


WDUJHWUDQJHPJG/PPRO/ERWKLQFOXVLYHGLYLGHGE\WKHWRWDOQXPEHURI
UHFRUGHGPHDVXUHPHQWV
7KHSULPDU\HVWLPDQGZLOOEHHVWLPDWHGE\WKHSULPDU\HQGSRLQWDQDO\VHGLQDOLQHDUPL[HGPRGHO
ZLWKWUHDWPHQWDQGSHULRGDVIL[HGHIIHFWVVXEMHFWDVDUDQGRPHIIHFWDQGZLWKDQXQVWUXFWXUHG
UHVLGXDOYDULDQFHPDWUL[
8VLQJWKHXQEOLQGHGGDWDDQGEHIRUH'%/YLVXDOWRROVZLOOEHXVHGWRGHWHUPLQHZKHWKHUWKHGDWD
LQFOXGLQJWKHSULPDU\HQGSRLQWDUHQRUPDOO\GLVWULEXWHG,ILWLVWKHQIRXQGWKDWWKHGDWDDUHQRW
QRUPDODQDSSURSULDWHWUDQVIRUPDWLRQZLOOEHSHUIRUPHGDQGWKLVZLOOEHGRFXPHQWHGLQD6$3RU
WKH'%/PLQXWHV
6XSHULRULW\RI,'HJ2'FRPSDUHGWR,*ODU8P/2'ZLWKUHVSHFWWRSHUFHQWDJHRIWLPHVSHQWLQ
JO\FDHPLFWDUJHWUDQJHZLOOEHFRQVLGHUHGFRQILUPHGLIQRQLQIHULRULW\LVFRQILUPHGDQGWKHORZHU
OLPLWRIWKHWZRVLGHGFRQILGHQFHLQWHUYDORIWKHGLIIHUHQFH,'HJ2',*ODU8P/2'LV
HQWLUHO\DERYH]HURRUHTXLYDOHQWO\LIWKHSYDOXHIRUWKHRQHVLGHGWHVWRI
+'DJDLQVW+$'!
LVVPDOOHUWKDQZKHUH'LVWKHHVWLPDWHGPHDQGLIIHUHQFHRIWLPHVSHQWLQJO\FDHPLFWDUJHW
UDQJH,'HJ2',*ODU8P/2'$VVXFKDIL[HGKLHUDUFKLFDOWHVWLQJSURFHGXUHZLOOEH
DSSOLHGZKLFKZLOOHIIHFWLYHO\DGMXVWIRUPXOWLSOHWHVWLQJ
1RQLQIHULRULW\ZLOOEHHYDOXDWHGE\FRPSDULQJWKHORZHUOLPLWRIWKHWZRVLGHGFRQILGHQFH
LQWHUYDOIRUWKHGLIIHUHQFHEHWZHHQ,'HJDQG,*ODU8P/WRDQRQLQIHULRULW\PDUJLQRIKK
,IWKHORZHU&,OLPLWLVDERYHQRQLQIHULRULW\ZLOOEHFRQVLGHUHGHVWDEOLVKHG7KH
WZRWDLOHGSYDOXHZLOOEHUHSRUWHGIRUWKHWHVWRIVXSHULRULW\
0LVVLQJGDWDGXHWRLQWHUFXUUHQWHYHQWVVXFKDVWULDOGLVFRQWLQXDWLRQLVQRWUHOHYDQWVLQFHWKHSULPDU\
HVWLPDQGLVEDVHGRQWKH33DQDO\VLVVHW
$VHQVLWLYLW\DQDO\VLVZLOOEHSHUIRUPHGWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHU
RI)*0UHDGLQJVZLWKLQWKHGHPDQG6SHFLILFDOO\WKHSULPDU\HQGSRLQWZLOOEHDQDO\VHGE\
DSSO\LQJWKHZHLJKWVWDWHPHQWLQWKHSURFPL[HGSURFHGXUHZLWKZHLJKWVFDOFXODWHGDVWKHVTXDUH
URRWRIWKHWRWDOQXPEHURI)*0UHDGLQJV
$QDGGLWLRQDOVHQVLWLYLW\DQDO\VLVZLOOEHSHUIRUPHGZKHUHDOOVXEMHFWVZKRKDYH)*0UHDGLQJVIRU
DWOHDVWVHYHQFRQVHFXWLYHGD\VZLOOEHLQFOXGHG:HLJKWLQJZLOOEHSHUIRUPHGDVGHVFULEHG
SUHYLRXVO\
)ROORZLQJVSHFLILFDWLRQVIURPWKHYHQGRUWKHDFFXUDF\RIWKH)*0PHDVXUHPHQWVFDQEHLQIOXHQFHG
E\LQWDNHRIHLWKHUDVFRUELFRUDQGVDOLF\OLFDFLG>@7KHOHYHORIFRQVHTXHQFHGHSHQGVRQWKH
DPRXQWRIWKHLQWHUIHULQJVXEVWDQFHDFWLYHLQWKHERG\>@'XHWRWKHWULDOGHVLJQGRVHVRIQRQ
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


GLDEHWLFFRQFRPLWDQWPHGLFDWLRQVDUHQRWFROOHFWHGDQGLWLVKHUHE\QRWSRVVLEOHWRLGHQWLI\KLJKULVN
VXEMHFWV$VHQVLWLYLW\DQDO\VLVZLOOEHSHUIRUPHGZKHUHDOO)*0PHDVXUHPHQWVIRUVXEMHFWVLQWKH
33DQDO\VLVVHWFRLQFLGLQJZLWKLQWDNHRIDVFRUELFDQGRUVDOLF\OLFDFLGZLOOEHH[FOXGHG7DNLQJ
ZDVKRXWSHULRGVRIERWKDVFRUELFDQGVDOLF\OLFDFLGDOVRDSSOLFDEOHIRUPXOWLYLWDPLQVLQFOXGLQJ
DVFRUELFDFLGLQWRFRQVLGHUDWLRQ)*0PHDVXUHPHQWVRYHUODSSLQJWKHVWDUWWRHQGGDWHVRILQWDNH
RIHLWKHUGUXJGD\ZLOOEHRPLWWHGLQWKHDQDO\VLV7KLVZLOOUHVXOWLQSDUWLDORUFRPSOHWH)*0
SURILOHVEHLQJGLVUHJDUGHG:HLJKWLQJZLOOEHDSSOLHGDVGHVFULEHGSUHYLRXVO\WRDFFRXQWIRU
KHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI)*0UHDGLQJV

6HFRQGDU\HQGSRLQWV
6XSSRUWLYHVHFRQGDU\HQGSRLQWV
3HUFHQWDJHRIWLPHVSHQWLQWLJKWJO\FDHPLFWDUJHWUDQJHPJG/PPRO/ERWK
LQFOXVLYHLVFDOFXODWHGLQWKHVDPHZD\DVWKHSULPDU\HQGSRLQWXVLQJWKHUHOHYDQWUDQJHV$
VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI)*0
UHDGLQJVZLOOEHSHUIRUPHGDVGHVFULEHGSUHYLRXVO\
3HUFHQWDJHRIWLPHVSHQWLQQRFWXUQDOJO\FDHPLFWDUJHWUDQJHPJG/PPRO/ERWK
LQFOXVLYHLQWKHQRFWXUQDOSHULRGDP±DPERWKLQFOXVLYHZLOOEHFDOFXODWHGLQWKHVDPH
ZD\DVWKHSULPDU\HQGSRLQWEXWRQO\XVLQJUHDGLQJVZLWKDWLPHVWDPSLQWKHUHOHYDQWWLPHSHULRG
$VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI
)*0UHDGLQJVZLOOEHSHUIRUPHG$VGHVFULEHGSUHYLRXVO\WKHZHLJKWVDUHFDOFXODWHGEDVHGRQWKH
WRWDOQXPEHURI)*0UHDGLQJVDQGZLOOLQVRGRLQJQRWEHDGMXVWHGWRDFFRXQWIRUWKHORZHUQXPEHU
RIQRFWXUQDOUHDGLQJV
$OOWKHVXSSRUWLYHVHFRQGDU\HQGSRLQWVUHJDUGLQJWLPHVSHQWLQWDUJHWUDQJHDUHDQDO\VHGDQGWHVWHG
LQWKHVDPHPRGHODVWKHSULPDU\HQGSRLQWLHRQHVLGHGWHVWVRIWKHPHDQGLIIHUHQFHIDYRXULQJ
,'HJPXVWEHVWDWLVWLFDOO\VLJQLILFDQWO\GLIIHUHQWIURP]HURDWWKHOHYHOWRVXSSRUWVXSHULRULW\
$VVWDWHGLQ6HFWLRQRIWKHSURWRFROVLWHVDUHLQVWUXFWHGQRWWRLQLWLDWH)*0PRQLWRULQJ
SHULRGVWKDWZLOOFRQWDLQGD\OLJKWVDYLQJFORFNVKLIWV'XULQJGDWDDQDO\VLVLWZLOOEHFKHFNHGLIWKLV
UXOHLVREH\HGDQGWKHOHQJWKRIERWKWKHHQWLUHGD\LQTXHVWLRQLQJHQHUDODQGWKHQRFWXUQDOSHULRG
LQTXHVWLRQLQSDUWLFXODUZLOOEHDGMXVWHGHTXLYDOHQWO\ZKHQLWLVQRW)RUH[DPSOHLIDVXEMHFWLV
XQGHU)*0PRQLWRULQJLQWKH86RQ0$5WKHQRFWXUQDOSHULRGZLOOVWDUWDW$0DQG
HQGDWQRPLQDOVHQVRUWLPHLQVWHDGRI,QWKHGDWDDQDO\VLVRQHKRXUZLOOEHDGGHGWR
WKHUHFRUGHGWLPHSRLQWVIURPDQGRQZDUGV,QSUDFWLVHWKHQ0$5ZLOOFRQVLVWRIQR
PRUHWKDQKRI)*0UHDGLQJVDQGWKHQRFWXUQDOSHULRGRIQRPRUHWKDQKDQGPLQXWHVRI
)*0UHDGLQJV,IRQWKHRWKHUKDQGDVXEMHFWLVXQGHU)*0PRQLWRULQJRQ129LQWKH86
RQHKRXUZLOOEHGHGXFWHGIURPWKHWLPHUHFRUGHGWLPHSRLQWV7KLVZLOOWKHQFRQVLVWRIQRPRUH
WKDQKRXUVRI)*0UHDGLQJVDQGWKHQRFWXUQDOSHULRGRIQRPRUHWKDQKDQGPLQXWHVRI
)*0UHDGLQJV7KHKRXUEHWZHHQRQ129ZLOOEHUHSUHVHQWHGWZLFHLQWKHGDWD
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


DQGWRVHSDUDWHWKHPDQDX[LOLDU\YDULDEOHVWDWLQJLIDWLPHUHDGLQJLVLQWKHGD\OLJKWVDYLQJSHULRGRU
QRWZLOOEHDGGHGWRDOO)*0UHDGLQJV
7KHPHDQJOXFRVHOHYHOVPPRO/ZLOOEHFDOFXODWHGDVWKHPHDQRIWKH)*0JOXFRVHOHYHOVDQG
DQDO\VHGE\PRGHOVDQGWHVWHTXLYDOHQWWRWKHSULPDU\HQGSRLQW$VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWV
WRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI)*0UHDGLQJVZLOOEHSHUIRUPHGDV
GHVFULEHGSUHYLRXVO\
)*0UHDGLQJVKDYHDORZHUOLPLWRITXDQWLILFDWLRQ//24RIPJG/RUPPRO/DQGDXSSHU
OLPLWRITXDQWLILFDWLRQ8/24PJG/RUPPRO///24PDUNHGUHDGLQJVZLOOEH
DVVLJQHGWKH//24YDOXHDQG8/24PDUNHGUHDGLQJVZLOOEHDVVLJQHGWKH8/24YDOXH
0HDQ+E$FYDOXHVZLOOEHDQDO\VHGXVLQJDVLPLODUPRGHODVFRPSDUHGWRWKHSULPDU\HQGSRLQW
EXWRQO\DVLQJOHWZRVLGHGWHVWIRUVWDWLVWLFDOO\VLJQLILFDQWGLIIHUHQFHVEHWZHHQ,'HJDQG,*ODU
8P/ZLOOEHSHUIRUPHG

([SORUDWRU\HQGSRLQWV
*O\FDHPLFYDULDELOLW\ZLOOEHFDOFXODWHGDVWKHVWDQGDUGGHYLDWLRQPPRO/DQGFRHIILFLHQWRI
YDULDWLRQRIWKH)*0JOXFRVHOHYHOVGXULQJWKHZHHNPDLQWHQDQFHWUHDWPHQWSHULRGV%RWK
ZLOOEHDQDO\VHGDQGWHVWHGZLWKPRGHOVDQGWHVWVHTXLYDOHQWWRWKHSULPDU\HQGSRLQW
0HDQLQVXOLQGRVHLQLQWHUQDWLRQDOXQLWVLVFDOFXODWHGDVWKHPHDQGRVHRYHUWKHPDLQWHQDQFH
WUHDWPHQWSHULRGVIRUHDFKVXEMHFW,WZLOOEHDQDO\VHGDQGWHVWHGXVLQJPRGHOVDQGWHVWVHTXLYDOHQW
WRWKHSULPDU\HQGSRLQW
3HUFHQWDJHRIWLPHVSHQWLQWKHK\SRJO\FDHPLFDOHUWUDQJHPJG/PPROOERWK
LQFOXVLYHDQGSHUFHQWDJHRIWLPHVSHQWLQWKHFOLQLFDOO\VLJQLILFDQWK\SRJO\FDHPLFUDQJH
PJG/PPRO/DUHFDOFXODWHGLQWKHVDPHZD\DVWKHSULPDU\HQGSRLQWXVLQJWKHUHOHYDQW
UDQJHV$VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJ
QXPEHURI)*0UHDGLQJVZLOOEHSHUIRUPHGDVGHVFULEHGSUHYLRXVO\
$OOWKHH[SORUDWRU\HQGSRLQWVUHJDUGLQJWLPHLQUDQJHDUHDQDO\VHGDQGWHVWHGLQWKHVDPHPRGHODV
WKHSULPDU\HQGSRLQWLHRQHVLGHGWHVWVRIWKHPHDQGLIIHUHQFHIDYRXULQJ,'HJPXVWEHVWDWLVWLFDOO\
VLJQLILFDQWO\GLIIHUHQWIURP]HURDWWKHOHYHOWRVXSSRUWVXSHULRULW\
1XPEHURIK\SRJO\FDHPLFHSLVRGHVPJG/PPRO/IRUDWOHDVWPLQXWHVDQGQXPEHU
RIK\SRJO\FDHPLFHSLVRGHVPJG/PPRO/IRUDWOHDVWPLQXWHVLQWKHQRFWXUQDOSHULRG
$0ERWKLQFOXVLYHZLOOEHFRXQWHGDVIROORZV$WOHDVWWZRFRQVHFXWLYH)*0
JOXFRVHUHDGLQJVLHUHDGLQJVWKDWIROORZHDFKRWKHUFRQWLQXRXVO\LQWLPHLQWKHVSHFLILHGUDQJH
DUHFRXQWHGDVDK\SRJO\FDHPLFHSLVRGH7ZRK\SRJO\FDHPLFHSLVRGHVPXVWEHVHSDUDWHGE\DW
OHDVWPLQXWHVDERYHWKHK\SRJO\FDHPLFUDQJHHTXLYDOHQWWRFRQVHFXWLYH)*0UHDGLQJVDERYH
WKHUHOHYDQWK\SRJO\FDHPLFUDQJHWREHFRXQWHGDVWZRRUPRUHHSLVRGHVLQVWHDGRIRQH)RUWKH
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI


QRFWXUQDOHSLVRGHVRQO\)*0UHDGLQJVLQWKHUHOHYDQWSHULRGZLOOEHXVHG3HUVRQ\HDUVRI
H[SRVXUH3<(ZLOOEHFDOFXODWHGDV
3<( 1B)*0PLQXWHVGD\V\HDUKRXUVGD\PLQXWHVKRXU
ZKHUH1B)*0LVWKHWRWDOQXPEHU)*0UHDGLQJVLQWKHUHOHYDQWSHULRG7KHQXPEHURI
K\SRJO\FDHPLFHSLVRGHVZLOOEHDQDO\VHGXVLQJDQHJDWLYHELQRPLDOUHJUHVVLRQZLWKWUHDWPHQWDQG
SHULRGDVIL[HGHIIHFWVVXEMHFWDVDQRUPDOO\GLVWULEXWHGUDQGRPHIIHFWDQGWKHORJ3<(DVDQ
RIIVHW$SYDOXHVPDOOHUWKDQIRUWKHRQHVLGHGWHVWRIWKHUDWHUDWLRLQIDYRXURI,'HJZLOOEH
FRQVLGHUHGDVVXSSRUWIRUVXSHULRULW\RI,'HJRYHU,*ODU8P/,IWKLVPRGHOGRHVQRWFRQYHUJH
D3RLVVRQUHJUHVVLRQPRGHOZLOOEHILWWHG


CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI



&KDQJHVWRWKHVWDWLVWLFDODQDO\VHVSODQQHGLQWKHSURWRFRO
8SGDWHVWRVHFWLRQLQSURWRFROYHUVLRQLVGHVFULEHGEHORZ

&RQWULEXWLRQWRSHUSURWRFRODQDO\VLVVHW
SLQVHFWLRQ
³7KH33DQDO\VLVVHWFRQVLVWVRIVXEMHFWVWKDWVWD\RQDVVLJQHGWUHDWPHQWXQWLODQGFRPSOHWH)*0
DVVHVVPHQWDWYLVLWVDQGUHVSHFWLYHO\´
,VUHSODFHGE\
³7KH33DQDO\VLVVHWFRQVLVWVRIVXEMHFWVWKDWVWD\RQDVVLJQHGWUHDWPHQWXQWLODQGFRPSOHWH)*0
DVVHVVPHQWDWYLVLWVDQGUHVSHFWLYHO\&RPSOHWH)*0DVVHVVPHQWLVVSHFLILHGDVVXEMHFWV
KDYLQJDWOHDVWRIWZRZHHNV)*0PHDVXUHPHQWVSHUPDLQWHQDQFHSHULRG
PHDVXUHPHQWV)*0PHDVXUHPHQWVIURPWKHILUVWKRXUVRIHDFKILWWHGVHQVRUDUHGLVUHJDUGHG
$OOHQGSRLQWDQDO\VLVZLOOEHSHUIRUPHGRQWKH33DQDO\VLVVHW
5DWLRQDOH7RHQVXUHXQDPELJXRXVGHILQLWLRQRISHUSURWRFRODQDO\VLVVHW

3UHVHQWDWLRQRIWHVWKLHUDUFK\
SLQVHFWLRQDIWHU
³,IWKHORZHU&,OLPLWLVDERYHQRQLQIHULRULW\ZLOOEHFRQVLGHUHGHVWDEOLVKHG´
,VDGGHG
³7KHWZRWDLOHGSYDOXHZLOOEHUHSRUWHGIRUWKHWHVWRIVXSHULRULW\´
5DWLRQDOH&ODULILFDWLRQWRHQVXUHOHJLEOHRXWSXWV

6SHFLILFDWLRQRIZHLJKWVIRUSULPDU\HQGSRLQW
SLQVHFWLRQ
³7KHSULPDU\HQGSRLQWZLOOEHWUDQVIRUPHGXVLQJLQYHUVHYDULDQFHZHLJKWLQJ6SHFLILFDOO\WKH
SULPDU\HQGSRLQWZLOOEHPXOWLSOLHGE\DZHLJKWFDOFXODWHGDVWKHLQYHUVHRIWKHVTXDUHURRWRIWKH
WRWDOQXPEHURI)*0UHDGLQJV´
,VUHSODFHGE\
³6SHFLILFDOO\WKHSULPDU\HQGSRLQWZLOOEHDQDO\VHGE\DSSO\LQJWKHZHLJKWVWDWHPHQWLQWKHSURF
PL[HGSURFHGXUHZLWKZHLJKWVFDOFXODWHGDVWKHVTXDUHURRWRIWKHWRWDOQXPEHURI)*0UHDGLQJV´
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI
5DWLRQDOH(QVXULQJWKDWIXOO)*0SURILOHVKDYHPRUHLPSDFWFRPSDUHGWRSDUWLDOSURILOHV

)XUWKHUVSHFLILFDWLRQRIZHLJKWVIRUSULPDU\HQGSRLQW
SLQVHFWLRQ
³,QYHUVHYDULDQFHZHLJKWLQJZLOOEHSHUIRUPHGDVGHVFULEHGSUHYLRXVO\´
,VFKDQJHGWR
³:HLJKWLQJZLOOEHSHUIRUPHGDVGHVFULEHGSUHYLRXVO\´
5DWLRQDOH'XHWRWKHFKDQJHLQ

6HQVLWLYLW\DQDO\VLVIRUSULPDU\HQGSRLQW
SVHFWLRQDIWHU
³$QDGGLWLRQDOVHQVLWLYLW\DQDO\VLVZLOOEHSHUIRUPHGZKHUHDOOVXEMHFWVZKRKDYH)*0UHDGLQJV
IRUDWOHDVWVHYHQFRQVHFXWLYHGD\VZLOOEHLQFOXGHG,QYHUVHYDULDQFHZHLJKWLQJZLOOEHSHUIRUPHG
DVGHVFULEHGSUHYLRXVO\´
,VDGGHG
³)ROORZLQJVSHFLILFDWLRQVIURPWKHYHQGRUWKHDFFXUDF\RIWKH)*0PHDVXUHPHQWVFDQEH
LQIOXHQFHGE\LQWDNHRIHLWKHUDVFRUELFRUDQGVDOLF\OLFDFLG>@7KHOHYHORIFRQVHTXHQFHGHSHQGV
RQWKHDPRXQWRIWKHLQWHUIHULQJVXEVWDQFHDFWLYHLQWKHERG\>@'XHWRWKHWULDOGHVLJQGRVHVRI
QRQGLDEHWLFFRQFRPLWDQWPHGLFDWLRQVDUHQRWFROOHFWHGDQGLWLVKHUHE\QRWSRVVLEOHWRLGHQWLI\
KLJKULVNVXEMHFWV$VHQVLWLYLW\DQDO\VLVZLOOEHSHUIRUPHGZKHUHDOO)*0PHDVXUHPHQWVIRU
VXEMHFWVLQWKH33DQDO\VLVVHWFRLQFLGLQJZLWKLQWDNHRIDVFRUELFDQGRUVDOLF\OLFDFLGZLOOEH
H[FOXGHG7DNLQJZDVKRXWSHULRGVRIERWKDVFRUELFDQGVDOLF\OLFDFLGDOVRDSSOLFDEOHIRU
PXOWLYLWDPLQVLQFOXGLQJDVFRUELFDFLGLQWRFRQVLGHUDWLRQ)*0PHDVXUHPHQWVRYHUODSSLQJWKH
VWDUWWRHQGGDWHVRILQWDNHRIHLWKHUGUXJGD\ZLOOEHRPLWWHGLQWKHDQDO\VLV7KLVZLOOUHVXOWLQ
SDUWLDORUFRPSOHWH)*0SURILOHVEHLQJGLVUHJDUGHG:HLJKWLQJZLOOEHDSSOLHGDVGHVFULEHG
SUHYLRXVO\WRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI)*0UHDGLQJV´
5DWLRQDOH$QDGGLWLRQDOVHQVLWLYLW\DQDO\VLVLVQHHGHGWRHYDOXDWHWKHLPSDFWRILQWDNHRIHLWKHU
DVFRUELFRUDQGVDOLF\OLFDFLGRQWKHDFFXUDF\RIWKH)*0PHDVXUHPHQWVGXULQJPDLQWHQDQFH
SHULRGV

6SHFLILFDWLRQRIZHLJKWVIRUVHFRQGDU\HQGSRLQW3HUFHQWDJHRIWLPHVSHQWLQWLJKW
JO\FDHPLFWDUJHWUDQJH
S VHFWLRQ
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI
³$VHQVLWLYLW\DQDO\VLVXVLQJWKHLQYHUVHRIWKHVTXDUHURRWRIWKHQXPEHURI)*0UHDGLQJVDV
LQYHUVHYDULDQFHZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI)*0
UHDGLQJVZLOOEHSHUIRUPHG´
,VUHSODFHGE\
³$VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI
)*0UHDGLQJVZLOOEHSHUIRUPHGDVGHVFULEHGSUHYLRXVO\´
5DWLRQDOH'XHWRWKHFKDQJHLQ

)XUWKHUVSHFLILFDWLRQRIZHLJKWVIRUVHFRQGDU\HQGSRLQW3HUFHQWDJHRIWLPHVSHQWLQ
QRFWXUQDOJO\FDHPLFWDUJHWUDQJH
SVHFWLRQ
³$VHQVLWLYLW\DQDO\VLVXVLQJWKHLQYHUVHRIWKHVTXDUHURRWRIWKHQXPEHURI)*0UHDGLQJVLQWKH
UHOHYDQWWLPHSHULRGDVLQYHUVHYDULDQFHZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJ
QXPEHURI)*0UHDGLQJVZLOOEHSHUIRUPHG´
,VUHSODFHGE\
³$VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI
)*0UHDGLQJVZLOOEHSHUIRUPHG$VGHVFULEHGSUHYLRXVO\WKHZHLJKWVDUHFDOFXODWHGEDVHGRQWKH
WRWDOQXPEHURI)*0UHDGLQJVDQGZLOOLQVRGRLQJQRWEHDGMXVWHGWRDFFRXQWIRUWKHORZHUQXPEHU
RIQRFWXUQDOUHDGLQJV´
5DWLRQDOH'XHWRWKHFKDQJHLQ

&ODULILFDWLRQRIVHFRQGDU\HQGSRLQW
S VHFWLRQ
³7KHPHDQJOXFRVHOHYHOVPJG/DQGPPRO/ZLOOEHFDOFXODWHGDVWKHPHDQRIWKH)*0JOXFRVH
OHYHOVDQGDQDO\VHGE\PRGHOVDQGWHVWHTXLYDOHQWWRWKHSULPDU\HQGSRLQW´
,VUHGXFHGWR
³7KHPHDQJOXFRVHOHYHOVPPRO/ZLOOEHFDOFXODWHGDVWKHPHDQRIWKH)*0JOXFRVHOHYHOVDQG
DQDO\VHGE\PRGHOVDQGWHVWHTXLYDOHQWWRWKHSULPDU\HQGSRLQW´
5DWLRQDOH0HDQJOXFRVHOHYHOVLQPJG/ZLOOQRWEHSUHVHQWHGLQWKHFOLQLFDOWULDOUHSRUW
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI

)XUWKHUVSHFLILFDWLRQRIZHLJKWVIRUVHFRQGDU\HQGSRLQWPHDQJOXFRVHOHYHOV
SVHFWLRQ
³$VHQVLWLYLW\DQDO\VLVXVLQJWKHLQYHUVHRIWKHVTXDUHURRWRIWKHWRWDOQXPEHURI)*0UHDGLQJVDV
LQYHUVHYDULDQFHZHLJKWVZLOOEHSHUIRUPHGWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJ
QXPEHURIUHDGLQJVSUVXEMHFWSUSHULRG´
,VUHSODFHGE\
³$VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI
)*0UHDGLQJVZLOOEHSHUIRUPHGDVGHVFULEHGSUHYLRXVO\´
5DWLRQDOH'XHWRWKHFKDQJHLQ

&ODULILFDWLRQRI8/24DQG//24LQ)*0GDWD
S VHFWLRQDIWHU
³7KHPHDQJOXFRVHOHYHOVPJG/DQGPPRO/ZLOOEHFDOFXODWHGDVWKHPHDQRIWKH)*0JOXFRVH
OHYHOVDQGDQDO\VHGE\PRGHOVDQGWHVWHTXLYDOHQWWRWKHSULPDU\HQGSRLQW$VHQVLWLYLW\DQDO\VLV
XVLQJWKHLQYHUVHRIWKHVTXDUHURRWRIWKHWRWDOQXPEHURI)*0UHDGLQJVDVLQYHUVHYDULDQFH
ZHLJKWVZLOOEHSHUIRUPHGWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURIUHDGLQJVSU
VXEMHFWSUSHULRG´
,VDGGHG
³)*0UHDGLQJVKDYHDORZHUOLPLWRITXDQWLILFDWLRQ//24RIPJG/RUPPRO/DQGD
XSSHUOLPLWRITXDQWLILFDWLRQ8/24PJG/RUPPRO///24PDUNHGUHDGLQJVZLOOEH
DVVLJQHGWKH//24YDOXHDQG8/24PDUNHGUHDGLQJVZLOOEHDVVLJQHGWKH8/24YDOXH´
5DWLRQDOH7RLQKLELWWKHLPSDFWRISURMHFWVWDQGDUGYDOXHVRQVHFRQGDU\PHDQDQGH[SORUDWRU\
VWDQGDUGGHYLDWLRQHQGSRLQWV

&ODULILFDWLRQRIH[SORUDWRU\HQGSRLQW
S VHFWLRQ
³*O\FDHPLFYDULDELOLW\ZLOOEHFDOFXODWHGDVWKHVWDQGDUGGHYLDWLRQPJG/DQGPPRO/DQG
FRHIILFLHQWRIYDULDWLRQRIWKH)*0JOXFRVHOHYHOVGXULQJWKHZHHNPDLQWHQDQFHWUHDWPHQW
SHULRGV´
,VUHGXFHGWR
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI
³*O\FDHPLFYDULDELOLW\ZLOOEHFDOFXODWHGDVWKHVWDQGDUGGHYLDWLRQPPRO/DQGFRHIILFLHQWRI
YDULDWLRQRIWKH)*0JOXFRVHOHYHOVGXULQJWKHZHHNPDLQWHQDQFHWUHDWPHQWSHULRGV´
5DWLRQDOH*O\FDHPLFYDULDELOLW\FDOFXODWHGDVWKHVWDQGDUGGHYLDWLRQLQPJG/ZLOOQRWEHSUHVHQWHG
LQWKHFOLQLFDOWULDOUHSRUW

6SHFLILFDWLRQRIZHLJKWVIRUH[SORUDWRU\HQGSRLQW3HUFHQWDJHRIWLPHVSHQWLQWKH
K\SRJO\FDHPLFDOHUWUDQJH
SVHFWLRQ
³$VHQVLWLYLW\DQDO\VLVXVLQJWKHLQYHUVHRIWKHVTXDUHURRWRIWKHQXPEHURI)*0UHDGLQJVDV
LQYHUVHYDULDQFHZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI)*0
UHDGLQJVZLOOEHSHUIRUPHG´
,VUHSODFHGE\
³$VHQVLWLYLW\DQDO\VLVXVLQJZHLJKWVWRDFFRXQWIRUKHWHURVFHGDVWLFLW\GXHWRDYDU\LQJQXPEHURI
)*0UHDGLQJVZLOOEHSHUIRUPHGDVGHVFULEHGSUHYLRXVO\´
5DWLRQDOH'XHWRWKHFKDQJHLQ
CONFIDENTIAL


6WDWLVWLFDO$QDO\VLV3ODQ
&21),'(17,$/
'DWH
-DQXDU\
1RYR1RUGLVN
7ULDO,'
9HUVLRQ

871
6WDWXV
)LQDO
(XGUD&7QR
3DJH
RI



5HIHUHQFHV

>@,$EERWW/DERUDWRULHV³)UHH6W\OH/LEUH'D\,QGLFDWLRQVDQG,PSRUWDQW6DIHW\,QIRUPDWLRQ´
>2QOLQH@$YDLODEOHKWWSVSURYLGHUP\IUHHVW\OHFRPVDIHW\LQIRUPDWLRQKWPO)6/VDIHW\LQIR
>$FFHVVHG-DQXDU\@


CONFIDENTIAL